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INTRODUCTION 
Pelvic exenteration surgery was first described in 1948 by Alexander Brunschwig in New York as a 
palliative procedure for unsalvageable cervical carcinoma and involves multi-visceral resection of 
pelvic tumours1. In 2016, pelvic exenteration is well established as a potentially curative option for 
locally advanced and recurrent pelvic tumours of the gastrointestinal, gynaecological or urological 
tract, where en bloc multi-visceral resection is performed with the aim of achieving clear resection 
margins2-4. Interestingly, the first published report of total pelvic exenteration in Australia was 
performed at Royal Prince Alfred Hospital, Sydney, in 1956 by a gynaecologist J. Cameron Loxton 
who spent three months with Dr Brunschwig in New York5.  
 
While the survival advantage of pelvic exenteration is confirmed, such radical resections may be 
associated with significant morbidity. A systematic review of contemporary literature by Yang and 
colleagues reported outcomes of pelvic exenteration of rectal cancer and documented a 53% median 
complication (range 37 – 100%) and median mortality rate of 2.5% (range 0 – 25%)6. Potential 
morbidity following pelvic exenteration depends on the extent of resection necessary for complete 
oncological clearance, i.e. which organs, neurovascular structures, soft tissues or bones are excised, 
and the subsequent reconstruction required. In patients requiring en bloc cystectomy for tumours 
involving the bladder, for example, urinary diversion is commonly achieved by construction of an 
ileal or colonic conduit. Major conduit-related complications include uretero-enteric anastomotic 
stricture or leak, fistulae or septic episodes7. Repair or reconstruction of major pelvic vessels may 
be required in selected patients following excision of tumours involving the common or external 
iliac vessels, and can be associated with postoperative deep vein or graft thrombus, haemorrahge or 
compartment syndrome8, however the literature is limited in reported outcomes of this subset of 
patients. As increasingly radical and potentially morbid resections are performed at the periphery of 
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the pelvis in pursuit of cure, such as high sacrectomy and lateral neurovascular excision, it is 
important to investigate postoperative morbidity with a view to reducing it.  
 
This thesis aimed to report the incidence of complications in particular subgroups of patients 
undergoing pelvic exenteration and identify factors which may predict these outcomes. Other 
postoperative outcomes including length of stay, oncological outcomes and survival were 
investigated. In chapter one the evolution of pelvic exenteration surgery over the 20th and 21st 
centuries is presented and provides an introduction and historical background for the thesis 
including a review of current literature. The study presented in chapter two investigated the 
incidence and risk factors for postoperative complications associated with urinary diversion (a 
major source of morbidity in exenteration patients) and compared patients who had urinary 
diversion as part of a pelvic exenteration with those who underwent cystectomy alone for primary 
bladder malignancy. Chapter three includes two studies which investigated the outcomes of lateral 
pelvic compartment exenteration, in terms of morbidity and survival, and explored the safety and 
feasibility of common or external iliac vessel resection and reconstruction. In chapter four, two 
novel surgical techniques which attempt to reduce morbidity associated with vascular 
reconstruction and high sacral resection (developed by the candidate’s primary supervisor, MJS) are 
presented. In chapter 4.1 a spiral saphenous vein graft technique for major pelvic vessel 
reconstruction during exenteration is presented. The existing literature reporting use of the spiral 
graft technique is reviewed and successful use for reconstruction of the common and external iliac 
artert and vein in a pelvic exenteration patient is reported. Chaper 4.2 presents a novel technique for 
en bloc resection of locally recurrent rectal cancer that invades the high sacral bone, where only the 
involved sacral segment is mobilised and excised en bloc, allowing preservation of uninvolved 
distal and contralateral sacral bone and nerve roots. The aim of this technique is to achieve 
complete oncological resection (i.e. a clear posterior bony margin) while maintaining structural 
6
Pelvic exenteration complications 	
	
stability of the pelvis and minimising neurological deficit associated with traditional sacral 
resection. Both techniques descrcibed in chapter 4 are the subject of ongoing investigation.  
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Abstract 
Pelvic exenteration was first described by Alexander Brunschwig in 1948 in New York as a palliative 
procedure for recurrent carcinoma of the cervix. Due to initially high rates of morbidity and 
mortality, the practice of this ultra-radical operation was largely confined to a small number of 
American centres for most of the 20th century. The post-World War II era saw advances in 
anaesthesia, blood transfusion and intensive care medicine which would facilitate the evolution of 
more radical and heroic abdominal and pelvic surgery. In the last three decades pelvic exenteration 
has continued to evolve into one of the most important treatments for locally advanced and recurrent 
rectal cancer. This review aimed to explore the evolution of pelvic exenteration surgery and identify 
the pioneering surgeons, seminal papers and novel techniques which have led to its current status of 
as the procedure of choice for locally advanced and recurrent rectal cancer. 
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Introduction 
Pelvic exenteration (PE) refers to radical multi-visceral resection of locally advanced or recurrent 
tumours of the pelvis. En bloc resection of all contiguously involved anatomical structures is 
performed with a view to achieving complete oncological (R0) resection. The primary justification of 
such radical surgery is the reasonable chance of cure which is now achievable in up to 63% of 
patients1-4. R0 resection is the most important factor in predicting survival and quality of life (QoL) 
after surgery5,6 and has therefore become the holy grail of PE.  
 
PE was first described in 1948 as a palliative procedure for recurrent carcinoma of the cervix, and has 
since evolved into one of the most important modalities for locally advanced and recurrent rectal 
cancer2. In the late 1940s and early 1950s, the survival outcomes were poor with operative mortality 
rates as high as 23-35%7,8. Due to these poor early outcomes the second half of the 20th century saw 
few centres practicing exenteration surgery in any meaningful numbers. Advances in anaesthesia, 
blood transfusion, medical imaging, intensive care medicine, patient selection and surgical 
techniques have allowed increasingly radical ‘higher and wider’ resections to be undertaken safely9. 
As a result, long term survival has become achievable with acceptable morbidity in selected patients 
at specialised units.  
 
This review aimed to trace the history of radical pelvic surgery from its first description in 1948 and 
identify the key steps in its technical evolution, including the pioneering surgeons, seminal papers 
and novel techniques, which have led to the current status of PE as a potentially curative option for 
locally advanced and recurrent rectal cancer. 
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1948: the Pioneers of Pelvic Exenteration 
In the 1930s and 40s the prognosis for cervical cancer was poor. Irradiation by radium and deep X-
ray therapy was the primary treatment, and local progression was common, with a cure rate of only 
20-30%10. Up to 42% of women who died from cervical cancer did so with disease still confined to 
the pelvis11. Terminal patients suffered from intractable pain, bowel obstruction and pyelonephritis or 
uraemia from ureteric obstruction. At this time palliative procedures for refractive pelvic pain 
included neurosurgical cordotomy, prefrontal lobotomy or alcohol injection into nerve roots12,13. The 
second World War saw significant advances in anaesthesia (particularly blood transfusion), 
antimicrobial therapy and management of critically ill patients, allowing increasingly radical surgery 
to become feasible. The first description of PE for these patients was published by Alexander 
Brunschwig at the Memorial Hospital (later Memorial Sloan Kettering Cancer Centre), New York, in 
1948 in which he described a ‘procedure of desperation since all other attempts to control the disease 
had failed’7. 
 
Brunschwig was a general surgeon with an interest in all areas of surgical oncology. Prior to 
describing PE, he was the first surgeon to report the single stage radical pancreaticoduodenectomy in 
193714, also known as Whipple’s procedure (Whipple had described radical 
pancreaticoduodenectomy as a two-stage procedure in 1935)15. Brunschwig had previously made 
several ‘desultory’ attempts at a three-stage operation for locally advanced rectosigmoid tumours in 
the 1930s, but never published his results as the ‘complications were serious and survival periods 
brief’16. Around the same time, Eugene Bricker had been independently performing exenteration-like 
procedures for rectal cancer at the Ellis Fischel Cancer Centre in Missouri from 1940 onwards, but 
due to poor outcomes and the interruption of World War II he did not publish at the time17. 
 
The original operation 
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In his original paper Brunschwig clearly stated the palliative intent of the procedure, and the only 
selection criteria were that disease must be confined to the pelvis7. Broadly, the operative approach 
was similar to that used today (figure 1). The patient was placed in the Trendelenburg position and 
dissection started at the aortic bifurcation and was carried down over the iliac arteries, ligating and 
dividing the ovarian vessels and resecting all iliac nodes. Bilaterally the internal iliac artery and vein 
were ligated and divided near their origin to enter a plane lateral to the vessels and the pelvic mass 
was retracted medially. The dissection was carried anteriorly, incising the peritoneal reflection over 
the anterior wall of the bladder to allow its mobilisation from the pubic symphysis. Both ureters were 
divided proximal to tumour and individually implanted into the sigmoid colon before it was 
transected distal to the ureters but proximal to the pelvic tumour18. The posterior dissection followed 
the concavity of the sacrum to finally allow complete isolation and mobilisation of the pelvic viscera. 
The abdominal wound was then closed with the end of the sigmoid incorporated as a stoma (a ‘wet 
colostomy’) at the inferior extent of the midline incision before the perineal approach was 
commenced (figure 1B).  
 
The patient was repositioned in the lithotomy position and an elliptical incision was made around the 
introitus and anus between the tip of the coccyx and the clitoris. The dissection was carried superiorly 
and laterally, levator ani muscles divided at their attachment to the bony pelvis and the specimen was 
delivered ‘en masse’ via the perineal wound. 
 
In Brusnchwig’s original series of 22 patients undergoing total PE, the intraoperative and 
postoperative mortality rates were 0 and 23% (5 patients) respectively, which he defended as  
‘not considered excessive and would compare favourable with the mortalities attendant upon the 
initial attempts at gastrectomy for cancer, total pneumonectomy, pancreaticoduodenectomy, combined 
abdominoperineal resection of the colon, and so on’7 
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Richard Boronow, a trainee of Brunschwig’s recalled working with him in New York, reminiscing 
that ‘Dr Brunschwig would do two exenterations – then start his office hours at 2:00 in the 
afternoon!’19. While some surgeons were enthusiastic about the new ultraradical procedure, many 
were critical and some considered it ‘a thoughtless form of mutilation, with limited chance of success 
for palliation, much less cure’19. 
 
1950s and 1960s: Beyond cervical cancer 
In the 1950s, Brunschwig, Bricker, and other pioneering surgeons went on to apply the new radical 
approach to malignancies arising from other pelvic viscera including the rectum. Brunschwig’s 
original 1948 series included the case of a man with advanced sigmoid cancer invading the trigone of 
the bladder, a segment of ileum and the vermiform appendix which were resected en bloc20. The 
patient remained disease free and well at 14 months follow up. Thompson and Howe reported the 
first case of complete pelvic evisceration for locally advanced rectal cancer in 195021, the same year 
that Brintnall and Flocks presented a series of nine patients requiring ‘en masse pelvic viscerectomy’ 
for rectal or sigmoid carcinoma, of which 3 died in the postoperative period22.  
 
In the following decades various units (mostly in America) gradually applied the new concept of ultra 
radical pelvic resection to cancer of the vulva23, ovary24,25, prostate26,27 and pelvic sarcomas28 
including embryonal rhabdomyosarcoma of the vagina in infants and children29,30. The first non-
malignant indication for PE was radiation necrosis of the pelvic viscera in 1951, which remained a 
relatively common reason for surgery while early radiation techniques including intra-cervical 
radium persisted31. The indications for PE were influenced by technology and refined surgical 
techniques over the following decades. The need for PE for cervical cancer declined, partly due to 
development of the cervical smear which allowed earlier recognition and the improvements in 
radiation therapy during the technological revolution from the 1960s onwards. Within a few years the 
13
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less radical ‘partial exenteration’ for anteriorly invading cervical tumours without rectal involvement 
had been described31, as was an extended PE with en bloc small bowel resection for involved loops32.  
 
Both Brunschwig and Bricker had traditionally performed the entire operation with a single surgical 
team by completing the abdominal approach first, before re-positioning the patient in the lithotomy 
position to commence the perineal dissection. The synchronous two team abdominoperineal PE used 
by most exenteration units today was adapted from rectal cancer surgery in 1959 by Schmitz and 
colleagues in Chicago33. The second half of the 20th century saw the rise of surgical specialisation, 
driven in part by World War II from which many surgeons returned home with experience in 
thoracic, reconstruction and orthopaedic surgery. Surgical subspecialisation ensued and drove the 
development of multi disciplinary surgical units, which would utilise the new subspecialist surgeon 
(plastic & reconstructive, urological, orthopaedic, vascular and neurosurgical) for various phases of 
the procedure, and undoubtedly contributed to improvements in morbidity and mortality (table 1). 
 
Urinary diversion 
One of the early challenges in refining the PE procedure was feasible reconstruction of the urinary 
system. Brunschwig’s ‘wet colostomy’ with ureteric implantation into the proximal colon was 
unsatisfactory and quickly superseded. After failed attempts to fashion a continent abdominal urinary 
reservoir from isolated sigmoid colon and caecum, Bricker described the ileal conduit in 195034 
which remains the workhouse of urinary diversion in 2016 (figure 2). 
 
A number of units soon described significant postoperative complications associated with urinary 
diversion, in particular the development of urinary fistulas8,35. Brunschwig showed that in patients 
who survived greater than five years after exenteration ‘the most frequent subsequent cause of death 
is the deterioration of the diverted urinary tract’36. He advocated for the early use of temporary or 
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permanent nephrostomy tubes, with ‘constant surveillance’ of the urinary diversion, and a low 
threshold for emergency nephrostomy for diversion of the urinary tract36. 
 
Today, en bloc cystectomy is required in 20-53% of patients undergoing PE2,37-39 and postoperative 
urological complications remain a major source of morbidity with longer hospital stays and increased 
mortality37. Compared to cystectomy alone for primary urological malignancy, urinary diversion may 
be associated with significantly higher urological morbidity in the context of irradiated, redo surgery 
and is reported between 9 and 24%, with 7 – 16% rate of urinary leaks (table 2)37-42. Techniques for 
continent urinary diversion which were developed in the 1980s have generally been avoided in PE 
patients at most centres due to concerns about higher complication rates, however recently some units 
have developed experience with these techniques which may be feasible in selected patients43. The 
technique of perineal urethrectomy to achieve a more antero-inferior margin in the male has recently 
been described44. 
 
1970s: Perineal Reconstruction 
In the 1970s focus turned to the high rate of septic complications following exenteration, particularly 
fistulas and abscesses, which were noted to arise in the irradiated empty pelvis in up to 15% of 
patients45. Surgical techniques were developed to address these problems and included the use of 
greater omentum to suspend the small bowel and urinary conduit out of the pelvic cavity and fill the 
dead space and at some units were associated with reduced fistula rates46,47. The use of locoregional 
myocutaneous flaps for perineal reconstruction was a significant advance in exenteration surgery 
which allowed both closure of large perineal defects not amenable to primary closure as well as 
transposition of healthy tissue into the pelvis to reduce perineal and septic complications48,49. These 
flaps are rotated into position in the perineum on their vascular pedicle and include the gracilis flap 
(which was the first myocutaneous flap described in 1976, figure 3)50, while other more commonly 
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used flaps are the rectus abdominus based on the inferior epigastric vessels51, and gluteus maximus 
flap52, due to their robustness and greater bulk. 
 
The 1970s also saw major technological advances leading to the development of intensive care units 
with mechanical ventilation and invasive monitoring, which contributed to the steady improvement in 
postoperative morbidity and mortality after radical cancer surgery. Early experiences with routine 
admission to an intensive care unit after PE in 1980, utilising ventilator support, ‘mini dose’ heparin 
and cardiac monitoring contributed to lower rates of respiratory and cardiac failure, thromboembolic 
events and mortality53 and has become the standard of care for all PE patients. 
 
1980s: Composite Pelvic Bone Resection 
Brunschwig and Barber published the first series of PE with composite bony resection in 1969 which 
included 28 patients (of 925 PEs) with en bloc resection of the pubis, ischium or sacrum54. Eight 
patients (29%) died in the operative period and only four patients (15%) survived more than five 
years. Although techniques for sacral resections for chordomas evolved in the orthopaedic literature 
over the following years55, these poor initial outcomes discouraged any further investigation of 
composite pelvic bone resection during PE over the next 20 years. 
 
The concept of sacrectomy was revisited in the 1980s by Wanebo and colleagues who described 
abdomino-prone sacral resection in 11 patients for recurrence of rectal cancer in the posterior pelvis 
(figure 4)56. After an initial abdominal phase with pelvic dissection and mobilization of involved 
organs, the patient was repositioned for prone en bloc sacrectomy and clear resection margins were 
achieved in all patients with two postoperative deaths. Takagi et al utilized this technique in a prone 
completion sacrectomy following abdominoperineal total PE for en bloc resection of the involved 
sacrum57. The work of Wanebo and Takagi prompted interest in the role of composite sacral 
16
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resection for recurrent rectal cancer and set the scene for various units to undertake these radical 
resections in the 1990s and 2000s (table 3), producing contemporary morbidity rates of 40 to 91%, 
mortality less than 5% and 28 – 46% 5-year survival58-62. 
 
More recently several units have developed alterative techniques for en bloc sacral resection which 
avoid the traditional complete sacrectomy in an attempt to minimize morbidity. Hemisacrectomy, 
resection of the anterior cortex of the sacrum to preserve nerve roots and segmental sacrectomy have 
been proposed as alternative techniques however this literature is largely limited to case reports63-66. 
The technique of abdomino-lithotomy sacrectomy to resect the lower sacrum (below S3) en bloc has 
recently been described67.  
 
Lateral pelvic sidewall excision 
Tumour involvement of the lateral pelvic sidewall has traditionally been considered an absolute 
contraindication to curative surgery at most units, largely due to the technical difficulty of achieving 
a clear resection margin safely where the tumour abuts or involves major neurovascular structures or 
lateral pelvic bone. However, as early as 1949 Brunschwig described ‘resection of the great veins of 
the lateral pelvic wall’ in order to gain clearance of laterally extending gynaecological tumours68. In 
1967 Barber and Brunschwig reported a series of 55 patients undergoing PE with radical en bloc 
common or external iliac vessel excision69, of which only 5 patients had vessel reconstruction using a 
graft as; 
‘The precarious condition of the patient, as well as the fact that the procedure is often carried out in a 
grossly contaminated and frequently previously heavily irradiated field and often with visible 
radiation changes in the large vessel, precluded the use of any type of graft in most instances’69 
The three patients with arterial excision alone all died within 30 days of surgery with gangrene of the 
ipsilateral lower limb, none of the eight patients with arterial and venous resection were alive at 5 
years and of 45 patients with venous excision alone were 5 surviving at 5 years. Due to these poor 
17
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early outcomes the contemporary literature is limited and patients with involvement of the sidewall, 
and particularly the common or external iliac vasculature, are generally not candidates for curative 
surgery70-75. 
 
Despite the lower rates of R0 resection as well as poorer survival outcomes for patients with lateral 
pelvic sidewall invasion (table 4)70,76,77, Wanebo reported composite resection of the ilium or ischium 
for laterally invasive tumours in five patients of which four survived between 3 and 6 years in 198778. 
More recently, en bloc resection of the pelvic side wall for advanced and recurrent rectal cancer 
involving lateral neurovascular structure has been described and has produced encouraging 
oncological and survival outcomes (table 4)79. Similar techniques have been reported in the 
gynaecological literature for cervical cancer80. 
 
A small number of contemporary units have developed experience with ‘higher and wider’ lateral 
resections for tumour involvement of the common and external iliac vessels81,82, and extending to the 
sciatic nerve and ischial bone83,84. These early studies have reported R0 resection rates of 38-58% in 
patients undergoing vascular excision and reconstruction, no perioperative mortality, and 96-100% 
long term graft patency81,82. These emerging reports may justify further investigation of more radical 
vascular excision and reconstruction in selected PE patients in the future. 
 
Conclusion 
Radical pelvic cancer surgery has evolved since PE was first described in 1948 and it now represents 
a potentially curative treatment for patients with locally advanced or recurrent pelvic tumours. 
Technical aspects of the procedure have been modified and refined over six decades, with notable 
developments including intestinal urinary conduits, composite pelvic bone techniques, lateral 
neurovascular excision and perineal reconstruction with myocutaneous flaps. Improved techniques, 
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advances in technology and critical care medicine have driven reductions in morbidity and mortality 
and improved survival rates over this time and understanding surgical anatomy has expanded the 
safety of wide excisions so that the paradigm is not ‘what can be exenterated’ but ‘what should be 
exenterated’. There remain unanswered questions around the repeated use of radiation and 
intraoperative brachytherapy, postoperative chemotherapy, synchronous metastatectomy, repeat 
exenteration for re-recurrent rectal cancer and the future role of laparoscopic and robotic surgery in 
exenteration. 	
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Table 1. Selected series reporting outcomes of pelvic exenteration surgery over seven decades 
Author 
Year Location Patients R0 (%) Mortality 
(%) 
Morbidity 
(%) 
5-year OS (%) 
 
Brunschwig7 1948 New York, USA 22 - 23 - - 
Brunschwig85 1965 New York, USA 430 - 18 - 22 
Ketcham86 1970 Maryland, USA 162 - 17 - 38 
Symmonds87 1975 Minnesota, USA 198 - 8 92 (early) 
88 (late) 
33 
Averette88 1984 Miami, USA 92 69 24 67 37 
Lawhead89 1989 New York, USA 65 54 9 - 23 
Robertson90 1994 Tyne, UK 83 - 4 47 41 
Salo91 1999 New York, USA 103 69 1 24* 31 
Heriot76 2008 Sydney & Melbourne, 
Australia 
Christchurch, NZ 
160 61 0.5 27 37 
You1 2012 Houston, USA 46 80 0 50 58 
Bhangu92 2014 London, UK 100 78 0 53 84 (PRC)** 
72 (RRC)** 
Harris2 2016 Multicentre 533 59 - - 28 
*requiring hospitalization or reoperation, **3-year overall survival,  OS overall survival -not reported, RRC recurrent rectal cancer, PRC primary rectal 
cancer 
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Table 2. Selected series reporting results of urinary reconstruction during pelvic exenteration 
Author 
Year Location No. 
patients 
Reconstruction (%) Overall 
urological 
morbidity (%) 
Urinary 
fistula/leak 
(%) 
R0 
(%) 
Mortality 
(%) 
Overall 
Survival Ileal 
conduit 
Colonic 
conduit 
Other 
Wrigley35 1976 Minnesota, USA 34 100 0 0 25 25 - 12 - 
Fallon93 1979 Iowa, USA 43 77 17 5 14 (early) 
14 (late) 
14 - - - 
Orr94 1982 Alabama, USA 115 84 16 0 - 9 - - - 
Russo42 1999 New York, USA 47 94 2 4 17 4 89 2 53% at 17 
months 
median 
follow up 
Houveneaeghel38 2004 Marseille, France 124 41 3 56 9 8 - 8 - 
Goldberg41 2006 New York, USA 103 63 0 37 - 14 - 1 47% (5yr) 
Stocchi95 2006 Cleveland, USA 82* 43 36 0 - 7 - 2 19% (5yr) 
Stotland39 2009 Toronto, Canada 126 75 5 20 24 9 - 0 - 
Teixeira37 2012 Sydney, Australia 74 64 36 0 - 16 70 0 - 
- not reported, *20 patients (24%) did not undergo urological reconstruction 
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Table 3. Selected series reporting results of en bloc sacrectomy for locally advanced or recurrent rectal cancer 
Author 
Year Location Patients Highest 
sacral level 
Blood loss, 
median, ml 
Operating 
time, 
median hrs 
R0 
(%) 
Mortality 
(%) 
Morbidity 
(%) 
Survival 
Median OS 
(months) 
5-year OS 
(%) 
Wanebo54 1981 New York, USA 11 S1/2 11.5 units 
transfused* 
11* 100** 18 - - 30** 
Takagi55 1983 Nagoya, Japan 5 S2/3 7400* 9.7* - 0 40 - - 
Temple84 1992 Calgary, Canada 9/11‡ S1/2 - - - 9 - 36* 18 
Magrini85 1996 Rochester, USA 14/16‡ S2/3 3350 12.5 69 0 69 - 48 (2-yr) 
Wanebo86 1999 Providence, USA 53 L5/S1 - - 74 8 - 36 31 
Zacherl87 1999 Vienna, Austria 12 S1/2 17.4 units 
transfused* 
8.6* 100 0 42 21.7* 17 (3-yr) 
Gonzalez88 2003 Denver, USA 41/45‡ - - - 73 4 56 - 31 (DF) 
Melton89 2006 New York, USA 29 S2/3 5 units 
transfused 
- 62 4 59 33 (DS) 20 (DS) 
Akasu90 2007 Tokyo, Japan 44 S2 3208 12.5 55 2 61 28 34 
Sagar57 2009 Leeds, UK 40 S2/3 3 units 
transfused 
- 50 2.5 60 55.6 DF*** - 
Ferenschild91 2009 Rotterdam, 
Netherlands 
25 S3 6500 8 77 0 68 32 30 
Bhangu92 2012 London, UK 30 S1/2 1725 9.5 68 0 50 - 76 (3-yr) 
Milne60 2014 Sydney, Australia 79/100‡ S1/2 4500 11.9 72 0 74 45*** 38*** 
Bosman93 2014 Eindhoven, 
Netherlands 
86 S2 6823 RRC* 
3506 PRC* 
- 56 5 - - 24 PRC 
28 RRC 
Colibaseanu58 2014 Rochester, USA 30 L4/5 2663 - 93 0 76 - 46 
Khaled94 2014 Toronto, Canada 19 S1/2 5000 10.4 100 5 79 77* - 
Uehara95 2015 Nagoya, Japan 32 S1/2 2653 16.5 77 0 91 - 76 (3-yr) 
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*mean, **patients undergoing curative surgery, ***patients with R0 resection, ‡ numerator is number of patients with rectal cancer and denominator is 
number of patients undergoing surgery, DF disease-free, DS disease-specific, OS overall survival -not reported, RRC recurrent rectal cancer, PRC primary 
rectal cancer
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Table 4. Selected series reporting results of lateral pelvic sidewall excision during pelvic exenteration 
Author Year Location No. patients 
Vascular 
reconstruction  
Blood loss, 
median, ml 
Operating time, 
median hrs 
R0 
(%) 
Mortality 
(%) 
Morbidity 
(%) 
Overall 
survival 
Barber67 1967 New York, USA 55 5 - - - 35 - 11% (5yr)* 
Yamada68 2001 Kagoshima, 
Japan 
17/60† 0 - - - 3 - 0% (5yr) 
Moore75 2004 New York, USA 12/119† 0 - - 17 9 - - 
Austin77 2009 Sydney, 
Australia 
36 8 6.6 units 
transfused 
9 53 0 70 69% at 19 
months mean 
follow up 
Solomon82 2015 Sydney, 
Australia 
200 23 3500 10.25 67 0.5 82 35% (5yr) 
* 35 patients with excision of iliac vein only,  †numerator is patients with lateral sidewall excision, denominator is all patients undergoing surgery,  -not 
reported 
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Figure 1 (A) Diagram showing levels of transection of the ureters (U) and colon (C) and incision 
encompassing the vulva and anus (PW) from Alexander Brunschwig’s original paper7. (B) Diagram 
showing conditions at end of operation indicating areas of peritonectomy (shaded area, P, P‘, PI’, 
PI”). The midline colostomy is shown with both ureters (U, U’) implanted into the colon a short 
distance above colostomy. Copyright © 1948 American Cancer Society. Reproduced with 
permission from John Wiley & Sons Ltd. 
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Figure 2 Diagram from Bricker’s original paper on urinary diversion34 demonstrating the evolution 
of various intestinal reconstruction techniques including bilateral ureteric anastomosis to an isolated 
segment of sigmoid colon (A), terminal ileum with caecal reservoir (B), caecum with terminal 
ileum for urinary drainage tract (C) and the contemporary ileal conduit (D). Copyright © 1950 
Surgical Clinics of North America. Reproduced with permission from Elsevier. 
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Figure 3 Diagram of the gracilis myocutaneous flap for reconstruction of the perineum after pelvic 
exenteration as described by McCraw and colleagues in 197650. Copyright © 1976 Plastic & 
Reconstructive Surgery. Reproduced with permission from Wolters Kluwer. 
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Figure 4 Diagrams from Wanebo’s first description of abdomino-prone sacral resection showing 
the extent of resection required for recurrence of rectal cancer in the posterior compartment (A), 
lines of transection of the sacrum from the posterior approach (B), the operative defect after sacral 
resection (C) and rotational skin flaps for wound closure (D)56. Copyright © 1981 J.B Lippincott 
Company. Reproduced with permission from Wolters Kluwer. 
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CHAPTER 2 
 
Urological complications after cystectomy as part of pelvic exenteration are higher than that 
after cystectomy for primary bladder malignancy 	
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Abstract 
Background:  Total cystectomy and subsequent reconstruction of the urinary tract may be required 
for primary malignancy of the bladder, or in the context of multi-visceral resection for more 
advanced pelvic tumours. Complications following urinary diversion are a major source of 
morbidity, particularly in pelvic exenteration (PE) patients. 
Methods:  All patients who underwent radical cystectomy alone or during PE at a single tertiary 
referral centre between 2008 and 2014 were reviewed. Postoperative urological complications were 
collected and compared between groups. 
Results:  231 patients underwent en bloc cystectomy (98 cystectomy alone, 133 as part of a 
PE). Postoperative urological complications occurred in 33% of the cystectomy alone group and 
59% of the PE group (P<0.001). PE for recurrence had higher complications than PE for primary 
malignancy (67% vs. 48%, P=0.035). Urological leaks occurred in 3, 6 and 14% of patient who had 
cystectomy alone, PE for primary malignancy and PE for recurrence. Major blood loss and previous 
pelvic radiotherapy independently predicted conduit-associated complications in PE patients (P= 
0.002 and 0.035). 
Conclusions:  Urological complications of cystectomy, particularly urine leaks and sepsis, are more 
common in patients undergoing PE compared to those with cystectomy alone. Prior pelvic 
radiotherapy, the extent of surgical resection and major blood loss may contribute to urological 
morbidity. 
 
Keywords: Cystectomy; pelvic exenteration; ileal conduit; urine leak; urinary diversion
Introduction 
The most common indication for radical cystectomy is a primary malignancy of the urinary tract 
such as those arising from the bladder, prostate or urethra. However, a radical cystectomy may also 
be required as part of an extended radical resection or pelvic exenteration (PE) for more advanced 
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malignancies of the pelvis, whether primary or recurrent. In any case, subsequent reconstruction of 
the urinary tract is required. While an ileal conduit is generally preferred, colonic conduits, wet 
colostomies or even orthotopic bladder are also options depending on the local surgical expertise 
and clinical situation.   
 
The oncological role of PE for locally advanced and recurrent pelvic malignancies arising from the 
anorectum, gynaecological or urological systems is now well established1-3. Depending on the 
anatomic location of the tumour or recurrence or the anticipated bladder function, an en bloc 
cystectomy may be required in 20-53% of all patients undergoing a PE3-6. Morbidity associated 
with cystectomy and its reconstruction can be considerable but in the setting of re-operative surgery 
where multi-visceral en bloc resection is required in an irradiated field, as is commonly the case in 
PE surgery for locally recurrent cancer, this morbidity is even more marked7,8. Several exenteration 
units have published urine leak rates in excess of 15% after conduit formation and this contrasts 
sharply against the urine leak rates in contemporary urological literature where a leak rate of <5% is 
generally reported following conduit formation for a primary urological malignancy4,8-14. Whether 
this disparity reflects true differences in complication rates between a more radical versus a less 
radical operation, primary versus re-operative surgery or whether this difference reflects 
institutional differences in complication rates or selection bias is unclear. The aim of this study was 
to compare urological complication rates between that of radical cystectomy or cystoprostatectomy 
alone for a primary urological malignancy and radical cystectomy or cystoprostatectomy as a part 
of a PE; as well as to identify factors that may inform and predict these urological complications 
which may impact on future surgical decision making.  
 
Methods 
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The study was conducted as part of a program of research exploring clinical and patient reported 
outcomes in PE surgery in Australia, funded in part through the Priority-Driven Collaborative 
Cancer Research Scheme by Cancer Australia and The Cancer Council Australia (ID 570860) and 
approved by the Royal Prince Alfred Hospital Human Research Ethics Committee. 
 
The study cohort included all patients who underwent radical cystectomy or total 
cystoprostatectomy either alone (non-PE group) or as part of a PE (PE group) at a single tertiary 
referral centre between 2008 and 2014 (inclusive). PE was defined as resection of the 
rectum/recurrent rectal cancer with en bloc resection of greater than 50% of two or more major 
unrelated organs and/or major pelvic neurovascular sidewall structures or bone. Patients who had 
partial cystectomy or who did not have reconstruction of the urinary tract after cystectomy (e.g. 
those with end-stage renal failure) were excluded. In female patients who underwent radical 
cystectomy for isolated bladder malignancy, an abdominal hysterectomy and/or bilateral salpingo-
oophorectomy was typically performed depending on previous gynaecological surgery and patient 
and surgeon preference. This was not considered pelvic exenteration (i.e. was not performed for 
tumour involvement) and these patients were included in the cystectomy alone group. 
 
PE patients were routinely staged using CT scan of the chest, abdomen and pelvis in addition to an 
MRI of the pelvis and a PET-CT scan. The decision to perform a cystectomy or cystoprostatectomy 
is made at a PE multi-disciplinary team (MDT) meeting. Indications for en bloc cystectomy were 
usually for contiguous tumour involvement or anticipated poor urinary function either as a result of 
high sacrectomy or small residual bladder capacity. Patients undergoing cystectomy alone routinely 
had a CT scan of the abdomen, chest and pelvis. Bone scintigraphy or pelvic MRI were performed 
in selected patients where there was concerns about bony metastases or local invasion of adjacent 
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organs. Pathology and imaging were reviewed at a urological tumour MDT meeting where the 
decision to proceed to surgery was made.  
 
The method of reconstruction (i.e. ileal conduit, colonic conduit or orthotopic neobladder) was 
dependent on surgeon and patient preference. In PE patients, the choice of reconstruction also 
depended on the availability of healthy and non-irradiated small bowel as well as whether or not 
there had been a pre-existing colostomy. Neobladder reconstruction was not generally offered to PE 
patients. The surgical technique used for conduit construction has been previously described4,15. In 
brief, an isolated segment of ileum or colon was used to form the conduit with proximal ureter from 
outside the irradiated field where possible. The Bricker technique16 was used for uretero-enteral 
anastomoses over infant feeding tubes which were secured to the wall of the conduit or urostomy 
bag to prevent migration. The technique for orthotopic neobladder has also been previously 
described and in brief, approximately 50 cm of distal ileum was harvested, preserving the terminal 
ileum, and detubularised at the anti-mesenteric border. A Hautmann orthotopic neobladder was 
fashioned with continuous 3-0 absorbable sutures17. The Bricker technique was also used in these 
patients and the ileo-urethral anastomosis was sewn over a 20 Fr urinary catheter. 
 
Data for the cystectomy alone group were retrospectively collected from medical records.  
Data for PE patients were derived from a prospectively maintained electronic database 
supplemented by additional data collection from patient medical records. Cardiac comorbidities 
included ischaemic heart disease, valvular disease, cardiomyopathy and arrhythmias. Vascular 
comorbidities included thromboembolic, cerebrovascular or peripheral vascular disease, or history 
of dissection or aneurysm. A urine leak has previously been defined as the presence of creatinine 
rich effluent from abdominal drains or wound sites, and/or radiological evidence of contrast 
extravasation from the conduit itself or ureteric anastomosis15. 
40
Pelvic exenteration complications 	
	
 
Statistical analysis was performed using SPSS software (IBM SPSS Statistics Version 22.0, IBM 
Corp., Armonk, NY). The chi square test was used to compare groups and identify univariate 
predictors of complications. Fisher’s exact test was used where samples contained less than five 
patients. Continuous variables were analysed using the independent samples t-test or median test for 
nonparametric data. P values were considered significant if less than 0.05. 
 
Results 
Over the study period, a total of 231 patients required en bloc cystectomy or cystoprostatectomy. Of 
these, 98 underwent cystectomy or cystoprostatectomy alone and 133 underwent cystectomy or 
cystoprostatectomy as part of a PE. During the same time period, there were 304 PEs performed 
(44% requiring en bloc cystectomy). The median age of the study cohort was 65 (range 15 – 94) 
and 173 (75%) were male. A total of 111 patients (48%) had a postoperative complication related to 
urinary diversion and the median length of hospital stay was 23 days (range 9-189). Table 1 
compares baseline patient characteristics between cystectomy or cystoprostatectomy alone patients 
and patients who underwent PE.  
 
Indications for cystectomy or cystoprostatectomy alone included transitional cell carcinoma (84%) 
or squamous cell carcinoma (3%) of the bladder, sarcoma (3%), neuroendocrine tumours (2%) and 
non-cancer indications (8%). In this group twenty (20%) and 14 (14%) patients had previously had 
pelvic radiotherapy and chemotherapy respectively. The majority (91%) had an ileal conduit formed 
for urinary reconstruction while the remaining 9% had an orthotopic neobladder. There were no 
colonic conduits in this group. Of 26 female patients in the cystectomy group, 14 patients (54%) 
also underwent hysterectomy with bilateral salpingo-oophorectomy at the time of surgery, 3 (12%) 
underwent oophorectomy, 2 (8%) underwent hysterectomy, 1 (4%) underwent vaginectomy. The 
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median length of stay of patients undergoing cystectomy alone was 18 days (range 9-116) during 
which time 32 patients (33%) had a complication related to the urinary diversion.  
 
In the PE group, 48 (36%) patients had their operation for primary malignancy, 84 (63%) for 
recurrent malignancy and one (1%) for chronic pelvic sepsis following a perforated rectal tumour 
(Table 2). 54 patients (41%) in this group had neoadjuvant chemotherapy and 124 patients (93%) 
had previously had pelvic radiotherapy, of whom 55 (45%) had this as part of a planned 
neoadjuvant regime. An ileal conduit was formed in 108 (81%) of PE patients, while the remaining 
25 patients (19%) had a colonic conduit. Orthotopic neobladders were not performed in PE patients. 
En bloc radical sacrectomy was performed due to posterior tumour invasion in 80 patients (60%), 
while 23 (17%) required radical excision of pubic bone in order to achieve clearance of the tumour 
anteriorly. The perineum was reconstructed using a regional myocutaneous flap in 53 PE patients 
(40%), while primary closure was possible in the remaining 80 patients (60%). 
 
Patients who underwent cystectomy or cystoprostatectomy alone had a higher median age than 
those undergoing PE (72 vs. 61 years, P < 0.001), a lower rate of previous pelvic radiotherapy (20% 
vs. 93%, P < 0.001) as well as a higher rates of cardiac comorbidity (32% vs. 15%, P = 0.003), 
diabetes mellitus (26% vs. 12%, P = 0.007) and renal impairment (41 vs. 15%, P < 0.001) (Table 1). 
The median length of hospital stay for patients who had cystectomy or cystoprostatectomy alone 
and PE was 18 and 28 days respectively (P < 0.001). 
 
The overall rate of postoperative complications associated with urinary diversion was 33% in the 
cystectomy or cystoprostatectomy alone group and 59% in patients undergoing PE (48% for 
primary vs. 67% for recurrent malignancy, P = 0.035) (Table 3). The most common conduit-
associated complication in all groups was postoperative urinary tract infection (UTI), which was 
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more common in patients who had PE for recurrent malignancy compared to those undergoing 
cystectomy alone or PE for primary malignancy (50%, 21% and 26%, P < 0.001). There was no 
difference in the rate of UTI between patients undergoing cystectomy alone and PE for primary 
malignancy (26% vs. 21%, P = 0.534). UTI was associated with an increased median length of stay 
in PE patients (P = 0.002) but not in patients who had cystectomy alone (P = 0.202). Urine leaks 
occurred in 3, 6 and 14% of patient who had cystectomy alone, PE for primary malignancy and PE 
for recurrence. The difference was not statistically significant between cystectomy alone and 
primary PE groups (P = 0.395). Median time from surgery to diagnosis of a urine leak was 11 days 
(range 2 - 63). The leak was managed conservatively in 4 (22%) patients. Eleven patients required 
radiological intervention (percutaneous nephrostomy tube placement) (61%) and three needed a 
reoperation (17%). 
 
A total of 10 patients required return to theatre for operations involving the urinary conduit, of 
which seven patients had had PE for recurrent malignancy (table 4). The reason for return to theatre 
was intraabdominal haemorrhage complicated by an ischaemic conduit (three patients), urine leak 
(three patients) and urostomy dehiscence (one patient). The remaining three patients required return 
to theatre for non-urological reasons (e.g. enterocutaneous fistula) during which the conduit was 
inadvertently injured during mobilization requiring repair. 
 
Univariate analysis of factors that predicted development of a complication associated with urinary 
diversion are summarised in table 5. Previous pelvic radiotherapy and greater than 5000 mL 
intraoperative blood loss independently predicted postoperative conduit-associated complications in 
PE patients (P = 0.035 and 0.002, respectively). There were no predictors of complications 
identified in patients with PE for primary malignancy. In patients undergoing PE for recurrent 
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malignancy, more than 5000 mL intraoperative blood loss predicted development of a postoperative 
complication (P = 0.038). 
 
In the pelvic exenteration group, diabetes, preoperative hypoalbuminaemia and greater than 5000 
mL intraoperative blood loss were factors associated with postoperative urological leaks, however 
this association did not reach statistical significance (P = 0.084, 0.073, 0.081). 
 
Discussion 
Urinary diversion after PE may be associated with higher rates of postoperative complications 
compared to patients undergoing cystectomy alone, however the literature in this area remains 
sparse3-6. This study reports the outcomes of 231 consecutive patients who underwent urinary 
diversion performed by the same urology unit between 2008 and 2014. The main findings of this 
study are that urinary diversion after PE is associated with higher complication rates, particularly 
when the indication is for recurrent malignancies. This difference in complication rates was found 
despite the cystectomy alone group being older and having higher rates of underlying 
cardiovascular disease, diabetes and renal impairment. Patients in the PE group had a higher rate of 
urine leaks and were also more likely to return to theatre either for a conduit related complication or 
during which the conduit is inadvertently injured, causing an intra-operative complication. High 
urine leak rates after PE have been previously reported4,8-11 and results of this study confirm a true 
difference in complication rates between these two groups of patients. 
 
The rate of postoperative conduit-associated complications was 33%, 48%, 67% in the cystectomy, 
primary malignancy PE and recurrent malignancy PE groups, respectively (P < 0.001). Although 
previously published series have reported complication rates between 17% and 24%7,8 these did not 
report rates of urinary tract infection (UTI), which was the most common complication in this 
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study, occurring in 40% of PE patients (21% for primary, 50% for recurrent malignancy) and most 
likely accounts for the disparately higher complication rate. Although low grade urosepsis managed 
conservatively would not traditionally be considered a major postoperative complication and is 
therefore not often reported, in this series it was common and prolonged the length of stay in PE 
patients and therefore remains a significant source of morbidity in this group of patients at our unit. 
Goldberg and colleagues documented a UTI or pyelonephritis in 36% of patients with urological 
reconstruction after PE, a result that is more consistent with the current study10 however this rate 
may be underestimated by the retrospective nature of their series. Interestingly, the rate of 
postoperative UTI was similar in patients undergoing cystectomy alone and PE for primary 
malignancy (26% vs. 21%, P = 0.534). 
 
Reported rates of postoperative urine leaks in pelvic exenteration patients range between 12-
16%4,10,11,15. These figures are considerably higher than the rate of urine leaks reported in patients 
undergoing radical cystectomy alone (usually less than 5%)12. It has been demonstrated that urine 
leaks after PE are a considerable source of morbidity that increase length of hospital stay and may 
convey a survival disadvantage in this group of patients4. In the current series 11% of pelvic 
exenteration patients developed a postoperative urine leak. The rate of urine leaks was high after PE 
for recurrence (14%), but lower in both PE for primary disease (6%) and cystectomy alone (3%). 
As with postoperative UTI, there was no statistically significant difference in the rate of urine leaks 
between the PE for primary malignancy and cystectomy alone group (P = 0.395). These results 
suggest that it is not simply the magnitude of the resection itself that contributes to urological 
morbidity but the fact that it is a major re-operative operation that is more relevant in increasing 
post-operative complications.  
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No patient or operative factors have been consistently shown to predict urological complications in 
PE patients, although cardiac disease, diabetes, major intraoperative blood loss, previous 
radiotherapy as well as type of urinary reconstruction have been implicated in this study. Reports of 
high rates of urological complications after preoperative radiotherapy9 were not replicated in a 
contemporary exenteration series by Stotland and colleagues8. Although a statistically significant 
association was identified between preoperative radiotherapy and urological complications in the 
current series (P = 0.035), almost all patients (93%) had received radiotherapy previously and 
therefore a small group of non-irradiated patients for comparison prevents any definite conclusions. 
Patients who had major intraoperative blood loss (> 5000ml) were more likely to experience a 
postoperative urological complication after PE. The increased risk of urological complication may 
be driven by a combination of pelvic irradiation and tissue hypoperfusion that is less common in the 
cystectomy patients. Interestingly there was no difference in complication rates between patients 
with colonic conduit or ileal conduits in the PE group. Most colonic conduits were fashioned 
because of the unsuitability (radiation and dense adhesions) of the ileum. 
 
Although this is the first study to compare urological outcomes in PE and cystectomy patients, there 
are limitations with the data. This includes retrospective data collection in the cystectomy group and 
small numbers in particular comparator groups (e.g. non-irradiated PE patients) which makes 
definite conclusions about predictors of urological complications difficult. 
 
In conclusion, patients undergoing urinary diversion for cystectomy performed in the context of PE 
are at substantially higher risk of postoperative urological complications compared to those with 
cystectomy alone. Urine leaks and sepsis are significantly higher in this group of patients and are 
associated with a longer hospital stay. Prior pelvic radiotherapy, the extent of surgical resection and 
major intraoperative blood loss may contribute to urological morbidity. 
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Table 1. Baseline information for patients undergoing urinary diversion in non-PE and PE groups 
  Non-PE (N=98) PE (N=133) p value* 
Age, years, median (range) 72 (41-94) 61 (15-86) <0.001† 
Gender     
   Male 72 (73) 101 (76) 0.669 
   Female 26 (27) 32 (24) 
Previous pelvic radiotherapy 20 (20) 124 (93) <0.001 
Neoadjuvant chemotherapy 14 (14) 54 (41) <0.001 
Comorbidities     
   Cardiac 31 (32) 20 (15) 0.003 
   Vascular 22 (22) 19 (14) 0.100 
   Diabetes 25 (26) 16 (12) 0.007 
   Other malignancy     
      Urological 14 (14) 15 (11) 0.477 
      Non-urological 12 (12) 10 (8) 0.217 
Preoperative albumin < 35 g/L 7 (7) 10 (8) 0.936 
Preoperative GFR < 60 ml/min/1.73m2 40 (41) 15 (11) <0.001 
Urinary reconstruction     
   Ileal conduit 89 (91) 108 (81) 
<0.001ǂ    Colonic conduit 0 (0) 25 (19) 
   Neobladder 9 (9) 0 (0) 
Intraoperative blood loss > 5000ml NA 45 (34)  
Length of stay, days, median (range) 18 (9-116) 28 (9-189) <0.001† 
Numbers in parentheses are percentage unless otherwise indicated 
NA: data not available 
* Test is chi square unless otherwise indicated 
† Median Test			
ǂ Fisher’s exact test
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Table 2. Origin of cancer in 133 patients undergoing urinary diversion during PE 
  Primary, N (%) Recurrent, N (%) Total (N) 
Rectal 37 (28) 60 (45) 97 
Anal SCC 2 (2) 11 (8) 13 
Sarcoma 2 (2) 2 (2) 4 
Bladder 2 (2) 1 (1) 3 
Prostate 1 (1) 2 (2) 3 
Colon  1 (1) 1 (1) 2 
Gynaecological     
   Cervical 0 (0) 2 (2) 2 
   Ovarian 0 (0) 2 (2) 2 
   Uterine 1 (1) 0 (0) 1 
   Vaginal melanoma 1 (1) 0 (0) 1 
   Vulval SCC 0 (0) 1 (1) 1 
Adenocarcinoma of unknown primary 1 (1) 0 (0) 1 
Rectal melanoma 0 (0) 1 (1) 1 
Neuroendocrine tumour 0 (0) 1 (1) 1 
Non-cancer     1 
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Table 3. Postoperative complication rates after urinary diversion during cystectomy alone or pelvic exenteration for primary or recurrent cancer 
  
Non-PE 
(N=98) 
PE – primary 
malignancy (N=48) 
PE – recurrent 
malignancy (N=84) 
p value* 
Non-PE vs. PE 
Non-PE vs. primary PE 
vs. recurrent PE 
UTI 25 (26) 10 (21) 42 (50) 0.027† <0.001† 
Urine leak 3 (3) 3 (6) 12 (14) 0.025 0.017 
Ureteric stricture 0 (0) 1 (2)  3 (4) 0.139 0.153 
Abdominal collection 7 (7) 10 (21) 22 (26) 0.001† 0.002† 
Postoperative haemorrhage 1 (1) 3 (6) 4 (5) 0.143 0.119 
Return to theatre 1 (1) 2 (4) 7 (8) 0.047 0.033 
Any conduit-related complication 32 (33) 23 (48) 56 (67) <0.001† <0.001† 
*Test is Fisher’s exact test unless otherwise indicated, † Chi square test, PE pelvic exenteration, UTI urinary tract infection 	
 
Table 4. Details of ten patients requiring return to theatre involving the urinary conduit 
Primary   
Operation Day Reason for return to theatre Description 
Non-PE 3 Urine leak Anastomoses resutured and omental patch 
PE 7 Urine leak Foley catheter eroded blind end of conduit. Primarily repaired. 
PE 10 Urine leak Hole in blind end of conduit. Resected with linear stapler. 
PE 0 Haemorrhage and ischaemic conduit Complete conduit revision 
PE 3 Haemorrhage and ischaemic conduit Ischaemic segment of conduit resected and reconstructed with small bowel 
PE 1 Haemorrhage Iatrogenic damage to conduit during dissection 
PE 35 Enterocutaneous fistula Iatrogenic damage to conduit during dissection. Conduit revised. 
PE 83 Enterocutaneous fistula Small bowel used to extend conduit to allow mobilisation. One ureter re-implanted onto the extension 
PE 8 Incarcerated small bowel hernia Iatrogenic damage to conduit near urostomy during dissection. Urostomy resited. 
PE 10 Urostomy dehiscence Stoma revised 
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Table 5. Univariate predictors of postoperative conduit-related complications comparing non-PE 
and PE patients 
  Patient had a conduit-related complication* 
  Non-PE (N=98) PE (N=133) 
Age >70 0.764 0.863 
Gender 0.811 0.214 
Comorbidity    
   Cardiac 0.373 0.631 
   Vascular 0.614 0.097 
   Diabetes 0.615 0.417 
   Urological malignant 0.745 0.960 
   Urological non-malignant 0.740† 0.675† 
   Other malignancy 0.575† 0.529 
Previous pelvic radiotherapy 0.777 0.035† 
Neoadjuvant chemotherapy 0.376† 0.397 
Reconstruction type 0.468† 0.331 
Preoperative Albumin < 35 g/L 0.595† 0.526† 
Preoperative GFR < 60 ml/min/1.73m2 0.681 0.510 
Intraoperative blood loss > 5000ml NA 0.002 
* Test is chi square unless otherwise indicated 
NA: data not available 
† Fisher’s exact test 
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Abstract 
Background: Pelvic exenteration involving the lateral compartment remains a relative or absolute 
contraindication in most units. Initial exenteration experience in our unit revealed a 21% clear 
margin rate (R0) which improved to 53% with early results adopting a novel technique for en bloc 
resection of the iliac vessels and other sidewall structures. The objective of this study was to report 
morbidity and oncological outcomes in 200 consecutive exenterations involving the lateral 
compartment. 
Methods: Patients undergoing pelvic exenteration between 1994 and 2014 were eligible for review. 
200 patients with en bloc resection of the lateral compartment were included. 
Results: R0 resection was achieved in 66% of patients undergoing surgery for cancer (197 patients) 
and 69% of planned curative resections. For patients with colorectal cancer, a clear resection 
margin was associated with a significant overall survival benefit (P=0.030). Median overall and 
disease-free survival in this group was 41 and 27 months, respectively. The overall 1-, 3- and 5-year 
survival rates were 86%, 46% and 35%, respectively. No predictors of survival were identified on 
univariate analysis other than margin status and operative intent. Excision of the common or 
external iliac vessels or sciatic nerve did not confer a survival disadvantage. 
Conclusion: The continuing evolution of radical techniques of pelvic exenteration has seen the 
improvement in R0 margin status (the “holy grail” of pelvic exenteration) from 21 to 66% over a 
20-year period by adopting routinely a more lateral anatomic plane. 5-year overall survival rates are 
comparable to more centrally-based tumours.
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Introduction 
Pelvic exenteration offers potentially curative treatment to patients with locally advanced and 
recurrent tumours of the pelvis. Contemporary literature demonstrates acceptable morbidity and 
quality of life associated with these radical multi-visceral resections,1 which confer overall 5-year 
survival up to 65%.2-5 As a result, exenteration is now accepted as a safe and feasible option for this 
group of patients with otherwise incurable disease. Increasingly more radical resections are being 
successfully undertaken in order to achieve clear resection margins, which is considered the most 
important predictor of survival.6, 7 Despite this, the role of pelvic exenteration in the management of 
tumours involving the lateral sidewall of the pelvis remains controversial. Due to proximity to the 
pelvic bone and major neurovascular structures, achieving en bloc excision with a clear lateral 
resection margin is technically challenging,8 particularly in the setting of previous surgery and 
radiotherapy. This group of patients have been shown to have poorer survival when compared to 
those with tumours involving the other compartments of the pelvis.2, 9 As a result, extensive pelvic 
sidewall involvement has traditionally been considered a contraindication to surgery and this group 
of patients remain precluded from a curative operation in many units.9-15 
 
A previously described radical approach to advanced primary or recurrent pelvic malignancies 
involving the pelvic sidewall has demonstrated the oncological feasibility of exenteration in this 
group of patients without increased morbidity.16 This technique involves en bloc resection of pelvic 
sidewall structures including the internal iliac vessels, piriformis and obturator internus muscles, 
ischium, and sacrotuberous and sacrospinous ligaments. The objective of this study is to report the 
postoperative and oncological outcomes of 200 consecutive patients undergoing pelvic exenteration 
with en bloc lateral iliac vessel excision at a single centre. 
 
Patients & Method 
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Patients who had a pelvic exenteration at Royal Prince Alfred Hospital between 1994 and 2014 
were eligible for review. 200 patients with en bloc resection of the lateral compartment defined by 
at least a complete resection of all or a significant part of the internal iliac vessel system as part of 
their operation were identified from a prospective electronic database and included in this study. All 
patients underwent thorough clinical review and preoperative imaging in order to confirm 
resectability of the locally recurrent or advanced tumour, the patient’s fitness for surgery and the 
presence of irresectable metastatic disease. All patients were reviewed at a specialised exenteration 
multi-disciplinary team (MDT) meeting, attended by a radiologist, oncologist, and colorectal, 
orthopaedic, vascular, plastic and urological surgeons. Pre-operative PET-CT and MRI were used to 
assess the extent of lateral tumour invasion into the sidewall which guided the extent of dissection. 
CT or MR angiography and venography was performed in patients where tumour closely 
approximated the common or external iliac vessels to further assess involvement. If en bloc 
resection of the vessels with subsequent reconstruction was anticipated the patient was reviewed 
clinically by a vascular surgeon and further investigations (such as venous Doppler studies of the 
lower limbs assessing suitability for harvesting) conducted as required.  
 
Surgical Procedure 
A detailed anatomical understanding of the lateral pelvic sidewall and lumbosacral triangle is 
critical when considering the operative approach to laterally extending pelvic tumours (paper under 
peer review). A technique for dissection and en bloc resection of the iliac vessels and other sidewall 
structures to achieve clear lateral resection margins has been described16 and is summarised in this 
section. Similar techniques have been reported in the gynaecological literature.17 
 
After division of adhesions and mobilisation of small bowel loops from the pelvis, the common and 
external iliac artery (CIA, EIA) and vein (CIV, EIV) are dissected starting proximally at the apex of 
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the Triangle of Marcille and the bifurcation of the aorta and inferior vena cava and proceeding 
distally to the origin of the internal iliac artery (IIA) and vein (IIV). At this point ureterolysis is 
performed with a cuff of alveolar tissue to preserve blood supply. If en bloc ureterectomy is 
indicated the ureter is divided proximal to the point of involvement by the tumour. After the EIA 
and EIV are dissected, the internal iliac artery (IIA) and vein (IIV) are ligated and divided at their 
origins. Where the tumour encases or adheres to the common iliac vessels, part or all of the 
involved vessel is excised en bloc with the tumour to gain a clear margin, which is done in 
preference to attempting to dissect the vessel free of tumour. Techniques for repair or reconstruction 
of the common and external iliac vessels using autologous and synthetic grafts have been 
previously described18, 19 and should be performed immediately to minimise the risk of 
compartment syndrome and thrombosis.  
 
Suture ligation of the IIA and IIV at their origins allows partial devascularisation of the pelvic 
viscera and allows access to their branches and tributaries which are then dissected, ligated and 
divided. Mobilisation and gentle medial retraction of the tumour mass is then possible and gives the 
surgeon access to a lateral plane of dissection. By dissecting laterally to the internal iliac vessels, 
the deep pelvic fascia covering the lumbosacral trunk and sacral nerve roots on the piriformis 
muscle are exposed. The piriformis muscle, sciatic nerve distal to the ischial spine, obturator 
internus and levator muscles are dissected free from the bony pelvic sidewall and, if required, the 
ischium and sacrotuberous and sacrospinous ligaments can be resected using energy devices and an 
osteotome. If sacrectomy is required, it can be performed via an anterior abdominal approach if the 
level of division is below S3 or otherwise completed in the prone position according to established 
principles.20-24 
 
Data Collection 
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Medical records of included patients were reviewed and the data extracted included patient 
demographics, details of their cancer, operation details, pathological analysis findings, resection 
margin status, postoperative complications, length of stay and survival data. Major complications 
were defined as those requiring re-operative or radiological intervention or which prolonged the 
expected length of hospital stay. Resection margins were categorised as microscopically clear of 
malignant cells (R0), microscopically involved (R1) or macroscopically involved (R2).  
 
Statistical analysis was completed using SPSS software (IBM SPSS Statistics Version 22.0, IBM 
Corp., Armonk, NY). Kaplan-Meier survival curves were used to estimate patient survival 
outcomes, which were compared using the log-rank test to identify univariate predictors of survival. 
Patient with non-colorectal malignancy were excluded from the survival analysis. A significant P 
valve was defined as less than 0.05. 
 
The study was conducted as part of a program of research exploring clinical and patient reported 
outcomes in pelvic exenteration surgery in Australia, funded in part through the Priority-Driven 
Collaborative Cancer Research Scheme by Cancer Australia and The Cancer Council Australia  (ID 
570860) and approved by the Royal Prince Alfred Hospital Human Research Ethics Committee. 
 
Results 
Of 398 pelvic exenterations during the study period, en bloc iliac vessel excision was performed in 
200 cases (50%). 120 patients (60%) were male and the median age was 60 years (range 15-83). 77 
patients (39%) in the series had radiotherapy prior to surgery either as neoadjuvant therapy or 
during treatment of their primary tumour in some cases of recurrence. Demographic and operation 
details of 200 patients in this series are summarised in Table 1. There were 183 curative operations 
(92%) and 93 patients (47%) had a bladder-sparing procedure. The majority of patients had a pelvic 
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exenteration for locally recurrent rectal cancer (100, 50%) or advanced primary rectal cancer (32, 
16%) while squamous cell carcinoma of the anus and gynaecological malignancies accounted for 
10% and 6%, respectively (Table 2). Three patients had a non-cancer indication for surgery; 
including chronic pelvic sepsis secondary to a previously perforated primary rectal tumour, 
diverticular mass thought to be malignant disease and pelvic fibromatosis.  
 
103 patients (52%) had a total cystectomy, which was performed en bloc with subsequent urinary 
diversion in the form of an ileal or colonic conduit (77% and 23%, respectively). One patient on 
haemodialysis for end stage kidney disease did not have urinary reconstruction. Resection of the 
sciatic nerve was required in 27 patients (14%) in this series and ischium in 22 (11%). One or both 
of the common or external iliac artery or vein were resected en bloc with the tumour in 29 patients 
(15%), of which 23 had repair or reconstruction of the vessel while six were ligated without 
reconstruction due to presumed collateral circulation from preoperative occlusion by thrombus or 
local tumour compression. 
 
Morbidity 
Overall a postoperative complication occurred in 164 patients (82%). The major and minor 
complication rates were 28% and 79%, respectively, and are summarised in Table 3. Sepsis was the 
most common postoperative complication and occurred in 100 patients (50%). Where sources of 
sepsis were identified, these were recorded as urological (31%), intra-abdominal (14%), wound-
related (12%), intravenous line-related (5%) and pulmonary (3%). The most common reasons for 
reintervention were drainage of pelvic collections (13%) and percutaneous nephrostomy tube 
insertion or conduit revision for urological leaks following urinary diversion (14%). In 47 patients 
with a flap, seven required return to theatre for debridement following flap breakdown (5%). The 
most common minor complication was urinary retention, which occurred in 26% of patients with a 
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bladder-sparing procedure. Other minor complications included motor neurological deficit (17%), 
cardiac arrhythmia (18%) and atelectasis (16%). 
 
Of the 29 patients who had en bloc resection of the common or external iliac, six required 
reintervention (21%). Three patients required laparotomy or angiography and stent insertion for 
abdominopelvic haematomas, although only two of these cases were due to dehiscence of the 
vascular graft. Two patients had thrombosis of the reconstructed vessel requiring thrombectomy in 
one patient and a venous and arterial bypass in another. One patient required lower limb fasciotomy 
on day 1 for compartment syndrome.  
 
Margin status and survival 
The overall rate of clear resection margins was 66% in patients undergoing surgery for cancer (197 
patients). This increased to 69% in those who had an operation with curative intent.  Margin status 
rates for tumours according to their origin are presented in Table 4. Notably, clear resection margins 
were achieved in 66% of patients with a planned curative resection of locally recurrent rectal 
cancer.  
 
For patients undergoing pelvic exenteration for colorectal cancer, a clear resection margin was 
associated with a significant overall survival benefit (P=0.030) (Figure 1). Median overall survival 
in this group was 41 months. The overall 1-, 3- and 5-year survival rates were 86%, 46% and 35%, 
respectively. The median overall survival was 29 months in patients with R1 margin status and 17 
months in patients with R2 margins. A clear resection margin also conferred a significant increase 
in disease-free survival (P=0.014), with a median of 27 months in this group. One patient died 
within 30 days of surgery (<1% mortality). No predictors of overall survival were identified on 
univariate analysis other than margin status and intent of the procedure (Table 5). Patients with 
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primary and recurrent tumours did not have a significantly different disease-free (P=0.393) or 
overall survival (P=0.334, Figure 2). Patients requiring excision of the common or external iliac 
vessels, ischial bone, or sciatic nerve did not have a survival disadvantage (P = 0.580, 0.201, 0.780, 
respectively). 
 
The median overall survival of patients with locally recurrent rectal cancer was 35 months. For 
patients with clear resection margins, median overall survival was 45 months (P=0.010) and 
disease-free survival was 27 months (P=0.006). In this subgroup the overall 3- and 5-year survival 
rates were 45% and 34%.  
 
Median follow up time of the study cohort was 3.2 years (range 0 – 18.5 years). 
 
Discussion 
Pelvic malignancies involving the lateral pelvic sidewall have previously been associated with 
lower clear resection margin rates and poorer survival compared to central, anterior and posterior 
tumours.2, 8, 9 Two recent Delphi studies carried out internationally among experts have confirmed 
that extensive pelvic sidewall involvement is considered a relative contraindication to curative 
surgery at many units and debate continues about the role of lateral iliac vessel resection.25, 26 This 
study reports the results of 200 consecutive cases of pelvic exenteration over 20 years with en bloc 
iliac vessel resection for locally advanced or recurrent cancer of the pelvis. R0 resection was 
achieved in 69% of patients who had an operation with curative intent. For colorectal cancer, this 
translated to a median overall survival of 41 months, a 3-year survival rate of 46% and a 5-year 
survival rate of 35%. These encouraging results improve on our units earlier experience with en 
bloc iliac (53% R0 resection) and support the use of this radical technique at specialised multi-
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disciplinary exenteration units in selected patients who should not be precluded from curative 
resection.  
 
The exenteration literature is limited regarding outcomes of patients undergoing surgery for 
tumours involving the pelvic sidewall. Moore and colleagues at Memorial Sloan-Kettering Cancer 
Centre reported R0 margins in 36% of tumours involving the lateral pelvic compartment and 19% 
in cases where pelvic sidewall involvement was suspected on preoperative imaging.8 Yamada and 
coworkers reported a 5-year survival of 0% in laterally invasive recurrence of rectal cancer and our 
institution contributed to a multicentre study that similarly demonstrated a survival disadvantage 
where there was lateral compartment involvement.2, 9 The current series presents improved results 
from experience with this technique that are comparable to reports in contemporary exenteration 
literature of median overall survival between 28 and 45 months and 5-year survival between 17 and 
65%.2, 14, 27-32 
 
In a consensus statement developed by The Beyond TME Collaborative, encasement of the external 
or common iliac vessels requiring en bloc excision and reconstruction was considered a relative 
contraindication to surgery by 78% of experts.26 In addition, various reviews have considered 
external or common iliac vessel involvement an absolute contraindication to surgery.11, 13 However, 
two recent studies have reported acceptable morbidity and R0 resection rates of 58% and 38% in 
patients with excision and reconstruction of major pelvic vessels 19 (paper accepted for publication). 
These encouraging reports in addition to the current series, which did not demonstrate a survival 
disadvantage after common or external iliac vessel excision, represent emerging literature which 
questions previously considered “irresectable” tumours for which curative resection may be 
possible in selected patients.7 It is possible that attempting to dissect the tumour off an involved 
vessel increases the likelihood of an involved lateral margin and for this reason it has been our 
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approach to plan a more radical en bloc excision based on preoperative imaging in these patients. 
Similarly, more lateral excisions involving en bloc resection of the sciatic nerve and ischial bone 
did not affect patient survival in this series. The St. Marks group recently reported initial outcomes 
of a modified technique for sidewall resection via an initial trans-gluteal approach to the sciatic 
notch with the patient prone.33 This approach does not allow an initial abdominal exploration to 
assess local invasion, metastatic disease or adhesiolysis and mobilisation of small bowel however 
clear resection margins were achieved all six patients in the series and further investigation of this 
technique is warranted. 
 
MRI is the imaging modality of choice for determining tumour resectability and guiding the extent 
of dissection during preoperative planning.25 Dresen and colleagues studied the accuracy of MRI in 
determining invasion of pelvic structures and confirmed its role in this setting with a negative 
predictive value of 93-100%, although the authors did report difficulty in determining pelvic 
sidewall involvement in some cases with diffuse post-operative or -radiotherapy fibrotic changes.34 
Georgiou and co-workers reported similar findings with the sensitivity of MRI being lower in the 
lateral compartment (89.3%) when compared to other pelvic compartments.35 Therefore MRI is 
critical for identifying planes for planned dissection however care must be taken when assessing the 
extent of pelvic sidewall invasion and should be interpreted by an experienced radiologist. This 
reinforces the need for a specialised MDT. 
 
Conclusion  
The continuing evolution of radical techniques of pelvic exenteration for advanced and recurrent 
pelvic malignancy has seen the improvement in R0 margin status (the “holy grail” of pelvic 
exenteration) from 21 to 68% over a 20 year period by adopting routinely a more lateral anatomic 
plane defined within the Triangle of Marcille. 
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Figure 1. Kaplan-Meier overall survival plot of patients undergoing pelvic exenteration for 
colorectal cancer (R0 vs R1/R2 resection, P = 0.030) 
 
Figure 2. Kaplan-Meier overall survival plot (primary vs. recurrent colorectal cancer, P = 0.334) 
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Table 1. Demographic information for patients undergoing pelvic exenteration with lateral iliac 
resection (N=200) 
Characteristic N (%) 
Gender  
Male 120 (60) 
Female 80 (40) 
Age, median (range), years 60 (15-83) 
Resection intent  
   Curative 183 (92) 
   Palliative 17 (9) 
Resected sidewall structures  
   Ureter 63 (32) 
   Piriformis muscle 10 (5) 
   Obturator muscle 27 (14) 
   Sciatic nerve 27 (14) 
   Femoral nerve 2 (1) 
   Obturator nerve 29 (15) 
   Internal iliac vessels 200 (100) 
   Common/External iliac vessels 29 (15) 
Urinary conduit (N=102)  
   Ileal 79 (40) 
   Colonic 23 (12) 
Bone resection (N=132)  
   Sacrectomy 107 (54) 
   Ischium 22 (11) 
   Pubis 17 (9) 
Reconstruction (N=47)  
   VRAM Flap 44 (22) 
   Gracilis flap 2 (1) 
   V-Y flap 1 (1) 
Margin status†  
   R0 126 (69) 
   R1 52 (28) 
   R2 5 (3) 
Blood loss, median (range), L 3.5 (0.0-25.0) 
Length of operation, median (range), min 615 (165-1200) 
Length of ICU admission, median (range), day 2 (0-27) 
Length of stay, median (range), day 25 (5-189) 
† n = 183 patients undergoing a curative resection 
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Table 2. Origin of cancer (N=200) 
Type of cancer Primary (%) Recurrent (%) Total 
Rectal 32 (16) 100 (50) 132 
Anal SCC 1 (1) 18 (9) 19 
Gynaecological    
    Ovarian 1 (1) 4 (2) 5 
    Uterine 1 (1) 0 (0) 1 
    Cervical 0 (0) 4 (2) 4 
    Vaginal melanoma 1 (1) 0 (0) 1 
    Endometrial 0 (0) 1 (1) 1 
Sarcoma 9 (5) 6 (3) 15 
Other    
    Colon 6 (3) 4 (2) 10 
    Bladder 3 (2) 1 (1) 4 
    Prostate 1 (1) 1 (1) 2 
    Neuroendocrine tumour 1 (1) 1 (1) 2 
    Perineal melanoma 0 (0) 1 (1) 1 
Non-cancer - - 3 
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Table 3. Postoperative mortality and morbidity for pelvic exenteration and lateral iliac resection 
(N=200) 
Complication N (%) 
Major Complications   
Wound/Flap   
   Wound dehiscence 3 (2) 
   Flap dehiscence 2 (1) 
   Partial flap necrosis 4 (2) 
   Full flap necrosis 1 (1) 
   Sacral osteomyelitis 2 (1) 
Cardiovascular   
   Myocardial infarction 2 (1) 
   Stroke 1 (1) 
   Pulmonary embolus 2 (1) 
   Haemorrhage 6 (3) 
   Vascular graft thrombosis 2 (1) 
   Thrombophlebitis 1 (1) 
   Compartment syndrome 2 (1) 
Gastrointestinal (reoperation)   
   Enterocutaneous fistula 3 (2) 
   Small bowel obstruction 5 (3) 
   Pelvic collection 26 (13) 
   Ischaemic ileostomy 1 (1) 
   Anastomotic leak 2 (1) 
Urological   
   Urological leak 14 (14)* 
   Renal calculi 1 (1) 
Minor Complications   
Wound/Flap   
   Infection 29 (15) 
   Minor wound dehiscence 20 (10) 
   Minor flap dehiscence 9 (5) 
Cardiovascular   
   Arrhythmia 36 (18) 
   Haemorrhage 3 (2) 
   Deep vein thrombosis 16 (8) 
Respiratory   
   Atelectasis 31 (16) 
   Pneumonia 15 (8) 
   Pulmonary oedema 3 (2) 
   Pneumothorax 2 (1) 
Gastrointestinal (conservative)   
   Enterocutaneous fistula 1 (1) 
   Small bowel obstruction 10 (5) 
   Pelvic collection 33 (17) 
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   Prolonged ileus 29 (15) 
Neurological   
   Sensory deficit 21 (11) 
   Motor deficit 34 (17) 
Renal/urological   
   Urinary retention 25 (26)† 
   Acute kidney injury 9 (5) 
   Hydronephrosis 5 (3) 
Postoperative transfusion 12 (6) 
Sepsis 100 (50) 
* N = 102 patients with urinary conduit 
† N = 97 patients with bladder-sparing operation 
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Table 4. R0 rates for lateral iliac resection by origin of cancer (N=197) 
Type of cancer R0 (%) R1/R2 (%) Total 
Primary rectal cancer 26 (81) 6 (19) 32 
Recurrent rectal cancer 62 (62) 38 (38) 100 
Anal SCC 11 (58) 8 (42) 19 
Gynaecological 9 (75) 3 (25) 12 
Other 23 (68) 11 (32) 34 
 
 
Table 5. Univariate predictors of survival of patients with colorectal cancer 
Characteristic Overall survival Disease-free survival 
Age > 60 0.241 0.759 
Male vs. female sex 0.913 0.799 
Curative intent 0.012 NA 
Primary vs. recurrent tumour 0.334 0.393 
R0 margin 0.030 0.014 
Blood loss > 5000ml 0.141 0.833 
Major complication 0.152 0.400 
Bladder-sparing operation 0.536 0.963 
Sacrectomy 0.128 0.054 
Common/external iliac excision 0.580 0.733 
Ischial bone resection 0.201 0.918 
Sciatic nerve excision 0.780 0.773 
NA = not applicable. 
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CHAPTER 3.2 
 
Outcomes following en bloc iliac vessel excision and reconstruction during pelvic exenteration	
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Abstract 
Background: Advanced pelvic cancers involving the lateral pelvic compartment, and particularly 
the iliac vasculature, are difficult to manage. Common or external iliac vessel involvement has 
traditionally been considered a contraindication for curative surgery. 
Objective: To investigate pathological and surgical outcomes particularly postoperative morbidity 
of pelvic exenteration with en bloc major iliac vascular excision and reconstruction.  
Design: A case series. 
Setting: A quaternary referral centre for pelvic exenteration in Sydney, Australia.  
Patients: Patients undergoing en bloc iliac vessel excision as part of their pelvic exenteration for a 
locally advanced pelvic malignancy. 
Main outcome measures: Over the study period, 336 patients underwent pelvic exenteration. 21 
patients (6.3%) underwent en bloc vascular excision of 29 vessels for tumour involvement. 24 
vessels required reconstruction. The primary outcomes were postoperative complications and 
pathological outcomes. Survival rates were estimated using Kaplan-Meier technique. 
Results: Operating time for patients who underwent vascular excision and reconstruction was 
longer but this did not reach significance (631 vs. 531 minutes, p=0.052). Mean blood loss was 
significantly higher in the vascular excision and reconstruction group (6.8 vs 3.4L, p<0.001). 
Patients who required en bloc vascular excision were less likely to have R0 margins compared to 
patients who did not (38% vs. 78%, p<0.001). There was no intra-operative or 30-day mortality. 
Overall graft patency and limb loss at one year was 96% and 0%, respectively. 52% of patients had 
at least one vascular related complication. Median overall and disease free survival were 34 and 26 
months, respectively.  
Limitations: This study is limited by a relatively small number of heterogeneous patients. 
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Conclusion: En bloc vascular resection and reconstruction for contiguous tumour involvement is 
feasible and safe in selected patients. Advanced pelvic tumours involving iliac vessels should not be 
precluded form curative surgery in specialised institutions.  
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Introduction 
Pelvic exenteration is an established procedure for patients with locally advanced or recurrent 
pelvic cancers where no other possibility of cure exists. Because of the magnitude of the procedure, 
surgery is generally offered when clear resection margins are likely. Pelvic side wall involvement 
and high sacral involvement have traditionally been considered contraindications for surgery. 
However, with improved surgical technique, many units with an exenteration interest have pushed 
the boundaries of “resectability” and redefined what in their experience constitutes “resectable 
disease”.  
 
In exenterative surgery, the lateral compartment typically poses the most challenge to the surgeon 
because of the major vascular and neural structures within that compartment. Either intended 
resection of or unintended injury to either of these can have disastrous surgical or functional 
consequences to the patient. Not surprisingly, extensive pelvic side wall involvement is typically 
considered an absolute contraindication for curative surgery.1-4 Because of technical difficulties in 
achieving R0 resection, tumours with pelvic side wall involvement typically have a worse prognosis 
compared to central or posterior recurrences.5,6 Previous authors have demonstrated the feasibility 
of en bloc vascular excision and reconstruction in conjunction with radical excisions of pelvic 
tumours. However, this experience is limited even within institutions with a subspecialty interest in 
recurrent pelvic malignancies.7, 8 
 
Due to the limited literature reporting pelvic exenteration with en bloc vascular excision and 
reconstruction, it remains unclear, firstly, whether or not iliac vessel involvement should be 
considered a contraindication for surgery, and secondly, if major vascular reconstruction contributes 
to patient morbidity. The aims of this study are to report the surgical outcomes and complications of 
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patients who underwent en bloc vascular excision and reconstruction as part of their pelvic 
exenteration. Pathology is also reviewed to determine R0 rates.  
 
Materials and Methods 
Patient Sample 
Patients who underwent pelvic exenteration for locally advanced or recurrent pelvic tumours 
between 1995 and 2013 at Royal Prince Alfred Hospital, Sydney, were identified from a 
prospectively maintained electronic database and formed the study cohort. The decision to perform 
excision and reconstruction of the common or external iliac vessels was based on the patient's 
clinical status and pre-operative imaging, reviewed at a pelvic exenteration multi-disciplinary team 
(MDT) meeting. All patients underwent CT of the chest, abdomen and pelvis and MRI of the pelvis. 
Over the course of this series positron emission tomography (PET) was increasingly utilised and is 
now a routine part of preoperative staging to rule out the presence of metastatic disease. Where 
imaging suggested involvement of pelvic vascular structures further assessment included CT or MR 
angiogram and duplex ultrasound studies of the lower limbs to assess extent of involvement of the 
vasculature, local tumour compression and to identify vessels suitable for autologous grafting.  
 
Operative Procedure 
Preoperative MRI was used to guide the extent of pelvic sidewall excision. If necessary, the rectum, 
ureter, sciatic nerve, piriformis, obturator internus or ischium were also excised en bloc in order to 
achieve clear resection margins. Surgical technique for tumours involving the lateral compartment 
of the pelvis has been previously described.8 The internal iliac vessels, which can generally be 
sacrificed during pelvic exenteration, were resected en bloc with the specimen without 
reconstruction after which the common and external iliac artery and vein were assessed for tumour 
involvement. Where there was infiltration of the vessel wall or a plane could not be developed 
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between it and the encasing tumour, en bloc resection of all or part of the vessel was performed in 
order to achieve an R0 resection. If the involved common or external iliac vessel could not be 
excised without functional sequalae (e.g. chronically occluded iliac vein with established 
collaterals) subsequent reconstruction was performed to restore vessel continuity and blood flow to 
the lower extremity.  
 
Technique for reconstruction depends on the extent of resection required and therefore the ensuing 
defect. Where only a cuff of the vessel wall is excised, repair was performed either primarily or 
using a patch repair. Where a segment of the vessel was excised, an interposition conduit graft was 
used for reconstruction. Both synthetic (polytetrafluoroethylene, PTFE) and autologous grafts 
(commonly superficial femoral or great saphenous veins) were used. Autologous graft material was 
preferred, when available, due to lower thrombogenicity and risk of infection.9 In selected cases 
where the common or external iliac vein was thrombosed from tumour compression pre-
operatively, vessel excision was performed without reconstruction. Where local vessel 
reconstruction was not possible, options for reconstruction include extra-anatomical bypass using a 
femoral-femoral cross-over bypass graft or, in the case of a vein, the contralateral great saphenous 
vein used for cross-over. These techniques were not necessary in this cohort as a primary 
reconstruction modality. 
 
Full-length compression stockings were applied postoperatively and prophylactic antibiotics were 
continued for five days. Limb vascular observations were performed every four hours for the first 
three post-operative days and these were then gradually reduced if no graft-related complications 
developed. Lower limb arterial and venous duplex ultrasonography was also performed routinely in 
hospital. Patients received subcutaneous heparin for the duration of hospital stay, which was 
changed to subcutaneous low molecular weight heparin following discharge if there had been a 
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postoperative thrombotic complication and where warfarin therapy was contraindicated. Patients 
were routinely followed up clinically by both the colorectal and vascular surgeons. Patients also 
routinely underwent 6 monthly duplex follow up to assess graft patency. For patients who 
underwent arterial reconstruction, ankle brachial indexes were also included as part of their duplex 
assessment.   
 
Data Collection and Analysis 
After ethical approval was granted by the Sydney Local Health District (RPAH Zone) human 
research ethics committee data was collected from medical records. Margin status was defined as 
R0 (margins clear of malignant cells), R1 (microscopically involved margins) and R2 
(macroscopically involved margin). Demographics, clinical characteristics and outcomes were 
compared for patients with and without vascular excision and reconstruction using the Mann-
Whitney U test for non-normally distributed data, while the Chi-square test (categorical variables) 
and independent-samples t-test (continuous variables) were used for normally distributed data. The 
survival outcomes were calculated using Kaplan-Meier curves with the log-rank test for comparison 
of these curves. Statistical analysis was performed using SPSS software (IBM SPSS Statistics 
Version 22.0, IBM Corp., Armonk, NY). 
 
Results 
Of 336 patients who underwent pelvic exenteration in the study period, excision of the internal iliac 
vessels was required in 164 patients (49%) to achieve complete tumour resection. 21 patients 
(6.3%) underwent 29 en bloc excisions of an external or common iliac vessel for tumour 
involvement. Demographic and clinical characteristics for these 21 patients are summarised in 
Table 1. The median age was 58 years (range 36 - 79) and 57% of patients were female. 
Involvement of pelvic vascular structures was identified on preoperative imaging in 16 patients, 
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while it was an intraoperative finding in 5 cases. Table 2 includes details of common and external 
iliac reconstructions performed in this series. Ten (48%), 3 (14%) and 8 (38%) patients had en bloc 
excision of vein, artery and both vein and artery, respectively. 21 vessel reconstructions were 
performed using interposition grafts (16 autologous, 5 synthetic), two had patch repair of the vessel 
and one was repaired primarily. The vessel could be excised without reconstruction in 5 patients 
because of pre-operative thrombotic occlusion. Mean intra-operative blood loss was 6.8L (range 
1.0-16.0L) and the mean length of hospital stay was 30 days (range 4 - 80). 
 
Clear resection margins (R0) were achieved in 38% of vascular patients vs. 78% of non-vascular 
reconstruction patients (p<0.001). On pathological analysis, there was tumour invasion or 
encasement of the vessel wall in 22 (76%) of the 29 excised vessels. Eight (38%) patients had R0 
resection margins, while 11 and two patients had R1 and R2 margins, respectively. Of the 11 
patients with R1 margins, 6 had involved margins at superior, distal or posterior margins away from 
the site of the iliac excision. Only seven were related to an involved lateral margin even more 
lateral to iliac vessel and in 4 of these 7, an even wider excision was precluded by bone (ilium or L5 
vertebrae) or soft tissue through the sciatic notch. Of the two patients with R2 resection margins, 
both had localised tumour perforation with an abscess cavity that was not appreciable on pre-
operative imaging and both had involved margins at the tumour cavity which was away from the 
iliac vessel itself. 
 
The median overall and disease-free survival of patients undergoing en bloc excision of the 
common or external iliac vessels was 34 and 26 months, respectively. 
 
Morbidity and Mortality 
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There was no operative or 30-day mortality in patients undergoing vascular excision and 
reconstruction and overall patency and limb loss at one year was 96% and 0%, respectively. 17 
(81%) patients had at least one postoperative complication (Table 3) although eight patients had a 
single minor complication that either did not prolong hospitalisation or only required medical 
management. Vascular specific complications occurred in 11 of 21 patients (52%). Of these 11 
patients, five that required reintervention. The median time to reintervention was 2 days (range 0 - 
24). Of those who underwent reintervention, one patient required evacuation of an abdominopelvic 
haematoma due to presumed bleeding from an autologous arterial graft anastomosis, however there 
was no active bleeding seen on intraoperative inspection of the vascular anastomosis. Another 
patient developed compartment syndrome in the leg ipsilateral to the arterial and venous 
reconstruction and underwent fasciotomy on day 1 after surgery. One patient haemorrhaged from 
dehiscence of a synthetic arterial graft due to secondary infection from an infected pelvic collection 
on day 24 and underwent emergency angiography and stent grafting. There were two patients that 
required reoperation for graft thrombosis. One underwent venous thrombectomy and insertion of an 
IVC filter for a thrombosed autologous venous graft. The second patient was found to have a 
pulseless, paralysed leg distal to the vascular reconstruction with paraesthesia and pain. Duplex 
ultrasound demonstrated thrombosis of the synthetic arterial graft and venous thrombosis distal to 
the point of ligation (without reconstruction). This patient underwent right common iliac artery and 
vein embolectomy with subsequent arterial femoral-femoral PTFE crossover graft and left great 
saphenous vein to right common femoral vein bypass graft. The other patients with vascular 
specific complications had a wound abscess at the vein harvest site (1), deep vein thrombosis at a 
site other than the reconstruction (2) and thrombosis of a venous reconstruction (3). Thrombosis of 
a venous graft occurred in five patients at a median of 2 days after surgery (range 0 - 9). 
Complications associated with arterial reconstructions (graft thrombosis, infection, dehiscence, 
compartment syndrome) occurred in 4 patients after a median time of 3.5 days (range 0 – 24). 
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Compared to 315 exenteration patients who did not undergo external or common iliac vessel 
excision and reconstruction, mean intra-operative blood loss was significantly higher in patients 
who had vascular reconstruction (6.8 vs. 3.4L, p<0.001), and mean operating time was longer (but 
did not reach statistical significance, 631 vs. 531 min, p = 0.052). However, this did not translate to 
a difference in mean length of hospital stay (30 vs. 28 days, p = 0.597). There was also no 
difference in the rate of complications between groups (p = 0.130) or the median number of 
complications per patient (1 vs. 1, p = 0.859).  
 
Discussion 
This study reports outcomes of 21 patients who underwent en bloc excision and reconstruction of 
iliac vasculature during pelvic exenteration and contributes to existing reports that major vascular 
excision and reconstruction is feasible and safe.7 Not surprisingly, vascular excision and 
reconstruction is associated with a longer operating time and higher blood loss but importantly, 
there was no operative mortality. Vascular specific complications however, occurred in just over 
half the patients and 50% of these were significant enough to require a repeat intervention. 
Although the R0 rates were lower compared to patients that did not require vascular excision, 38% 
of patients who would have been otherwise palliated now stand a chance of cure. As much as we 
are encouraged by the improved R0 results from this study, the R0 rates remain considerably lower 
than that of patients who did not require en bloc vascular excision and even better surgical 
techniques as well as better patient selection are needed to improve surgical and oncological 
outcomes. 
 
Traditionally, extensive tumour involvement of the pelvic sidewall or encasement of the common or 
external iliac vessels have been considered absolute contraindications to surgery.1, 2, 4, 10 Within our 
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unit, we have developed considerable experience with pelvic side wall excision including that of the 
internal iliac vessels but en bloc common or external iliac excision remains uncommon because 
these tumours are typically “higher” and “wider” and there are often other features on pre-operative 
staging that would preclude curative surgery. Therefore, this cohort of 21 patients represent a 
selected group of patients in a specialised centre. What the results of this study has demonstrated is 
that clear resection margins can be achieved in selected patients by en bloc resection of pelvic 
vascular structures during exenteration surgery (38% in the current series), and that major vascular 
reconstruction can be performed safely.  
 
Median overall and disease-free survival of patients undergoing resection of tumours with common 
or external iliac vessel involvement was 34 months and 26 months, respectively. Although 
heterogeneous tumour biology within this relatively small patient sample prevents any certain 
conclusions about long term survival, these outcomes are comparable to the large pelvic 
exenteration series which report overall median survival in the range of 21-43 months.11-15 Further 
investigation of long term survival rates in this group of patients is warranted. Even with these early 
results in a highly selected patient group, what this case series demonstrates is that involvement of 
the iliac vasculature by itself should not be an absolute contraindication for consideration of 
surgery.    
 
An approach to tumours involving the lateral pelvic sidewall has previously been described and 
early results with this technique included R0 resection in 53% of patients.8 A more recent series of 
200 consecutive patients undergoing pelvic exenteration with lateral compartment involvement 
demonstrated R0 resection in 66% of patients (paper under peer review). In the current series, clear 
resection margins were achieved in 38% of patients with en bloc vascular resection and 
reconstruction compared to 78% in patients without vascular reconstruction (p<0.001). The lower 
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R0 resection rate as well as the higher volume of blood loss and longer operation duration reflects 
the technically challenges that the pelvic sidewall presents to the operating surgeon and the more 
radical surgery that is required in this subgroup of patients. When the site of the involved margins 
were reviewed, what is clear is that it is invariably not the iliac vessel itself which determined the 
resection margins although it did increase the complexity of the procedure. What is clear on closer 
pathologic assessment of these specimens is that these are invariably extensive tumours with 
“higher” and “wider” involvement of other structures. It is possible also that the use of 
intraoperative radiation therapy (IORT) in patients with involved or close resection margins could 
reduce local recurrence, particularly those with R1, however this is not available at our institution. 
A recent case series by Abdelsattar and colleagues reported 12 patients who underwent radical 
resection of locally advanced and recurrent colorectal cancer involving the aorta or iliac vessels.7 
The current series results are comparable to the Mayo Clinic experience, which reported 0% 
mortality at 30 days and a 75% morbidity rate.  
 
The reconstruction technique for pelvic vascular structures after oncological resection is not well 
described. Small series and case reports have described reconstruction of iliac vasculature in the 
context of trauma,16 isolated nodal recurrence of colon cancer,17 and arterial graft infection,18 
however there are few published reports of major vessel reconstruction in the setting of pelvic 
exenteration.19-21 Twenty-one (72%) vessel reconstructions in this series required an interposition 
graft of which 16 were autologous grafts (most were the superficial femoral vein). Given the lack of 
guidelines for these patients, it is preferred that established vascular principles are adhered to, 
including the use of autologous graft material in preference to synthetic material where possible, in 
order to reduce the risk of graft thrombosis or infection. This is particularly important during pelvic 
exenteration, where the operative field may be contaminated by multiple bowel resections. Despite 
this, the current series includes a significant number of vascular complications and five patients 
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required reintervention, most of which were in the first week of the postoperative period. In the past 
our unit’s practice was to clamp the involved iliac vessels proximally and distally to gain 
haemostatic control, complete en bloc tumour resection and commence vascular reconstruction 
once the specimen was delivered. However, this practice has changed after a patient who developed 
postoperative compartment syndrome requiring multiple right leg fasciotomies and skin grafting. It 
is now preferred to reconstruct any involved vasculature immediately after they are divided even 
before the specimen is delivered as long as there is adequate access for the vascular team to perform 
their procedure. Abdelsattar and colleagues reported no graft-related complications, however in 
their series there was only one venous reconstruction and reconstructions tended to involve larger 
vessels (including the aorta) with higher flow rates, which may reduce the likelihood of distal 
anastomosis thrombosis and graft failure.7 The use of anti-coagulation after venous reconstruction 
can be helpful to prevent graft thrombosis but in exenteration patients, the use of anti-coagulation is 
limited by concerns of ongoing ooze from the large raw surgical bed that can result in a large pelvic 
haematoma. The seemingly high vascular specific complication rate may seem alarming at first. 
However, these outcomes are comparable to contemporary series of vascular reconstruction during 
sarcoma surgery where postoperative morbidity ranges from 36 - 71% and major wound healing 
complications are reported in up to 68%.22-25 Reintervention rates vary from 8 to 50% and limb 
salvage range from 84 – 100%.22, 24, 25 
 
In order to minimise morbidity, patients with extensive vascular involvement should undergo 
thorough preoperative assessment by a specialist vascular surgeon and be considered at a specific 
exenteration MDT meeting where likelihood of R0 resection is discussed and the sequence of 
surgical specialities planned meticulously. Preoperative thromboembolic disease should be assessed 
by clinical review and optimised by anticoagulation and IVC filter insertion where appropriate. 
Duplex ultrasonography should be routinely performed to assess local vessel compression by the 
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tumour, detect venous thrombosis and assess lower limb luminal diameters for potential harvest and 
grafting. A high index of suspicion should be maintained in the immediate postoperative period 
with four hourly clinical limb assessments and duplex ultrasound studies of the lower limbs distal to 
the graft such that graft-related complications are detected early and disastrous complications 
avoided. Extended antibiotic prophylaxis should be administered where graft reconstruction has 
been performed concomitantly with bowel resection. The use of spiral great saphenous autologous 
grafts tailored to the resected vessel diameter is currently being tested in our unit as an alterative to 
the superficial common femoral vein.26 
 
The limitations of this study are the highly selective nature of this series. The heterogeneous tumour 
biology within this relatively small patient sample limits our ability to draw definite conclusions 
about long term survival. There are also practical limitations in follow up for interstate and 
international patients that could have led to potential under reporting of complications following 
discharge, however most patients within this sample are enrolled in our main prospective quality of 
life study which would have capture ongoing health service utilisation and therefore complications 
or readmissions after discharge. 
 
Conclusion 
En bloc vascular resection and reconstruction is safe and feasible when performed at specialised 
institutions albeit the accompanying morbidity rates. Ongoing studies are required to clarify 
indications but within the confines of this early experience, these results are encouraging and in our 
opinion, iliac vasculature involvement by itself should not constitute absolute contraindication for 
an attempt at curative surgery although case selection is paramount. 
 
 
86
Pelvic exenteration complications 	
	
Acknowledgements 
The authors thank Lindy Maysa and Rachael Roberts for assistance with data collection. 
 
References 
1. Chew MH, Brown WE, Masya L, Harrison JD, Myers E, Solomon MJ. Clinical, MRI, and 
PET-CT criteria used by surgeons to determine suitability for pelvic exenteration surgery for 
recurrent rectal cancers: a Delphi study. Dis Colon Rectum. 2013;56:717-725. 
2. Sagar PM. Extended surgery for local recurrence and advanced rectal cancer. Colorectal 
Dis. 2006;8:43-6. 
3. Lopez-Kostner F, Fazio VW, Vignali A, Rybicki LA, Lavery IC. Locally recurrent rectal 
cancer: predictors and success of salvage surgery. Dis Colon Rectum. 2001;44:173-178. 
4. Pawlik TM, Skibber JM, Rodriguez-Bigas MA. Pelvic exenteration for advanced pelvic 
malignancies. Ann Surg Oncol. 2006;13:612-623. 
5. Heriot AG, Byrne CM, Lee P, et al. Extended radical resection: the choice for locally 
recurrent rectal cancer. Dis Colon Rectum. 2008;51:284-291. 
6. Bhangu A, Ali SM, Brown G, Nicholls RJ, Tekkis P. Indications and outcome of pelvic 
exenteration for locally advanced primary and recurrent rectal cancer. Ann Surg. 2014;259:315-
322. 
7. Abdelsattar ZM, Mathis KL, Colibaseanu DT, et al. Surgery for locally advanced recurrent 
colorectal cancer involving the aortoiliac axis: can we achieve R0 resection and long-term survival? 
Dis Colon Rectum. 2013;56:711-716. 
8. Austin KK, Solomon MJ. Pelvic exenteration with en bloc iliac vessel resection for lateral 
pelvic wall involvement. Dis Colon Rectum. 2009;52:1223-1233. 
9. Chlupac J, Filova E, Bacakova L. Blood vessel replacement: 50 years of development and 
tissue engineering paradigms in vascular surgery. Physiol Res. 2009;58:S119-139. 
10. Nielsen MB, Laurberg S, Holm T. Current management of locally recurrent rectal cancer. 
Colorectal Dis. 2011;13:732-742. 
11. Palmer G, Martling A, Cedermark B, Holm T. A population-based study on the management 
and outcome in patients with locally recurrent rectal cancer. Ann Surg Oncol. 2007;14:447-454. 
12. Asoglu O, Karanlik H, Muslumanoglu M, et al. Prognostic and predictive factors after 
surgical treatment for locally recurrent rectal cancer: a single institute experience. Eur J Surg Oncol. 
2007;33:1199-1206. 
87
Pelvic exenteration complications 	
	
13. Boyle KM, Sagar PM, Chalmers AG, Sebag-Montefiore D, Cairns A, Eardley I. Surgery for 
locally recurrent rectal cancer. Dis Colon Rectum. 2005;48:929-937. 
14. Wells BJ, Stotland P, Ko MA, et al. Results of an aggressive approach to resection of locally 
recurrent rectal cancer. Ann Surg Oncol. 2007;14:390-395. 
15. Hahnloser D, Nelson H, Gunderson LL, et al. Curative potential of multimodality therapy 
for locally recurrent rectal cancer. Ann Surg. 2003;237:502-508. 
16. Zamir G, Berlatzky Y, Rivkind A, Anner H, Wolf YG. Results of reconstruction in major 
pelvic and extremity venous injuries. J Vasc Surg. 1998;28:901-908. 
17. Uehara M, Yamamoto S, Fujita S, Akasu T, Moriya Y, Morisue A. Isolated right external 
iliac lymph node recurrence from a primary cecum carcinoma: report of a case. Jpn J Clin Oncol. 
2007;37:230-232. 
18. Gibbons CP, Ferguson CJ, Edwards K, Roberts DE, Osman H. Use of superficial 
femoropopliteal vein for suprainguinal arterial reconstruction in the presence of infection. Br J 
Surg. 2000;87:771-776. 
19. Ueda K, Nagayama H, Narita K, et al. Extended surgery with en bloc resection of the right 
common iliac vessels for lymph node metastasis of mucinous colon carcinoma: report of a case. 
Surg Today. 2001;31:238-241. 
20. Ali AT, Clagett GP, Edwards MJ. Complex venous and arterial reconstruction with deep 
vein after pelvic exenterative surgery: a case report. Am Surg. 2006;72:22-24. 
21. Bianchi C, Ballard JL, Bergan JH, Killeen JD. Vascular reconstruction and major resection 
for malignancy. Arch Surg. 1999;134:851-855. 
22. Ghert MA, Davis AM, Griffin AM, et al. The surgical and functional outcome of limb-
salvage surgery with vascular reconstruction for soft tissue sarcoma of the extremity. Ann Surg 
Oncol. 2005;12:1102-1110. 
23. Ghosh J, Bhowmick A, Baguneid M. Oncovascular surgery. Eur J Surg Oncol. 
2011;37:1017-1024. 
24. Schwarzbach MH, Hormann Y, Hinz U, et al. Clinical results of surgery for retroperitoneal 
sarcoma with major blood vessel involvement. J Vasc Surg. 2006;44:46-55. 
25. Song TK, Harris EJ, Jr., Raghavan S, Norton JA. Major blood vessel reconstruction during 
sarcoma surgery. Arch Surg. 2009;144:817-22. 
26. Brown KGM, Koh CE, Solomon MJ, Choy IC, Dubenec S. Spiral saphenous vein graft for 
major pelvic vessel reconstruction during exenteration surgery. Ann Vasc Surg 2015;29:1323–1326 
 
88
Pelvic exenteration complications 
Table 1. Demographic information for patients undergoing vascular excision and reconstruction 
(n=21) 
Characteristic n 
Age   
   <70 19 
   >70 2 
Gender   
   Male 9 
   Female 12 
Resection intent   
   Curative 17 
   Palliative 4 
Cancer presentation   
   Rectal   
         Primary 0 
         Recurrent 11 
         Re-recurrent 4 
   Osteosarcoma 1 
   Leimyosarcoma (recurrent) 1 
   Squamous cell carcinoma 1 
   Ovarian adenocarcinoma 1 
   Retroperitoneal sarcoma 1 
   Pelvic fibromatosis 1 
Radiotherapy   
   None 7 
   Neo-adjuvant 3 
   Prior < 2 years 3 
   Prior > 2 years 8 
Chemotherapy   
   Yes 14 
   No 7 
Previous thromboembolic disease   
   Yes 7 
   No 14 
Preoperative anticoagulation   
   Yes 5 
   No 16 
Margin status   
   R0 8 
   R1 11 
   R2 2 
Blood loss, mean (range), L 6.8 (1.0-16.0) 
Length of operation, mean (range), min 631 (220-1145) 
Length of stay, mean (range), day 30 (4-80) 
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Table 2. Details of vessel excision and reconstruction 
  
Arterial 
(n=11) 
Venous 
(n=18) 
Total 
(n=29) 
Technique       
   Primary repair 0 1 1 
   Patch 0 2 2 
   Interposition graft 10 11 21 
   Ligation without reconstruction 1 4 5 
Reconstruction material†       
   Synthetic 5 0 5 
          PTFE 5 0 5 
   Autologous 5 13 18 
          SFV 4 8 12 
          GSV 0 4 4 
          IIA 1 0 1 
          IIV 0 1 1 
Vessel involvement by tumour       
   Wall involvement 10 12 22 
   No involvement 0 5 5 
   Missing 1 1 2 
† n = 23 interposition grafts or patch repairs (i.e. not primary repair) 
SFV, superficial femoral vein; GSV, great saphenous vein; IIA, internal iliac artery; IIV, internal iliac vein; 
PTFE, polytetrafluoroethylene
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Table 3. Postoperative Complications for Pelvic Exenteration with Vascular 
Reconstruction (n=21) 
    
Complication n %  
Wound 3 14  
Gastrointestinal 7 33  
Stoma 0 0  
Neurological 4 19  
Urological 1 5  
Cardiovascular 5 24  
Respiratory 1 5  
Sepsis 7 33  
Vascular 11 52  
   Thrombosis of reconstructed vessel      
      Arterial† 1 10  
      Venous§ 5 36  
   Graft infection‡ 1 4  
   Deep vein thrombosis* 2 10  
   Pelvic haematoma 2 10  
   Wound healing complication 3 14  
   Compartment syndrome 1 5  
Reoperation (n=5)      
Thrombectomy 2    
Evacuation pelvic haematoma 1    
Graft stent insertion 1    
Fasciotomy 1    
†n = 10 arterial reconstructions 
§n = 14 venous reconstructions 
‡n = 23 interposition grafts or patch repairs (i.e. not primary repair) 
*At site other than graft (i.e. not thrombosis of reconstructed vessel) 
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CHAPTER 4.1 
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Abstract 
This article describes a great saphenous vein spiral graft technique for reconstruction of iliac vessels 
following en bloc resection during pelvic exenteration. Use of different size syringes as a scaffold 
allows the surgeon to construct autologous vascular interposition conduits of variable diameter to 
match the luminal size of the vessel requiring reconstruction. Autologous vascular grafts are 
preferred in exenteration surgery where the operative field is commonly contaminated by 
concomitant bowel resection, which carries an increased risk of graft infection. 
Keywords: Pelvic exenteration; Vascular Reconstruction; Interposition graft; common iliac artery 
reconstruction
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Introduction 
Multi-visceral en bloc resection with a view to clear resection margins is a key oncological 
principle in the management of locally advanced or recurrent cancers. Where there is contiguous 
tumour involvement of a major abdominal or pelvic vessel, en bloc vascular resection is performed 
with subsequent vessel reconstruction. Vascular reconstruction can be challenging in the presence 
of bowel and bladder resection where the operative field may be contaminated. The use of a 
synthetic vascular conduit in these circumstances is suboptimal because of the potential for graft 
infection, which can result in disastrous complications. However, this often proves necessary due to 
the major discrepancies in luminal circumference that autologous options may present and the 
additional concerns with leg oedema as a result of harvesting in post radiotherapy pelvises. This 
article describes a simple but effective spiral autologous graft technique that is used in our unit for 
the reconstruction of iliac vessels following pelvic exenteration.  
 
Case Presentation 
Figure 1 is a coronal MRI view of a 36-year-old man that shows a large retroperitoneal 
leiomyosarcoma. The patient presented with a sensation of abdominal fullness, distension and a 
palpable abdominal mass. There was compression flattening of the right psoas muscle and 
encasement of the right common iliac artery (CIA) and vein (CIV) and the right ureter. The tumour 
measured 14.2 cm by 9.9 cm axially and the superior mesenteric artery (SMA) lay centrally within 
the lesion. No bony invasion was evident and no metastases were identified. The case was reviewed 
at a specialised MDT (multi-disciplinary team) meeting and it was decided to proceed with surgical 
resection of the tumour with a plan for likely en bloc excision and reconstruction of the right CIA 
and CIV. 
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At laparotomy, the terminal ileum was adherent to and invaded by the tumour requiring en bloc 
resection of approximately 50cm of small bowel with the tumour. The sigmoid mesentery was 
intimately involved and was divided along the margin of the tumour, requiring resection of that 
segment of sigmoid colon. The SMA and ileocolic vessels were able to be dissected free of the 
tumour, while the right CIA and CIV were involved and to be removed en bloc with the specimen. 
The right ureter was also divided and a right nephrectomy performed. 
 
Bilateral GSV (great saphenous vein) harvest was performed and two spiral grafts were constructed 
using the technique described below (fig. 2) while the abdominal dissection was carried out. For 
reconstruction of the right CIA, a GSV spiral graft was constructed using a 5ml syringe and another 
for the right CIV using a 10ml syringe. The involved vessels were clamped and divided, allowing 
delivery of the specimen and reconstruction using the previously prepared interposition spiral grafts 
was performed. Figures 3 and 4 are intraoperative photographs showing the right CIV and CIA 
spiral interposition grafts in situ. After vascular reconstruction was complete and vessel clamps 
removed a high anterior resection was performed. Postoperatively, the patient had full-length 
compression stockings applied and was commenced on heparin (5000 units TDS). Lower limb 
circulation observations were performed four hourly in the immediate postoperative period to 
identify early limb ischaemia. Anticoagulation with warfarin was commenced postoperatively and 
prophylactic antibiotics were continued for five days. 
 
The patient experienced prolonged ileus postoperatively and required 13 days of total parenteral 
nutrition. He was discharged from hospital on day 21 after an otherwise unremarkable recovery and 
no concerns from a vascular perspective. At 5 months the patients ileostomy was reversed and 
duplex ultrasound confirmed that both arterial and venous spiral grafts were patent with no stenosis. 
Locally recurrent disease was demonstrated in the small bowel mesentery on a PET scan at 6 
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months. The recurrent tumour was resected requiring small bowel resection and anastomosis 
leaving the patient disease free. Since the patient had patent grafts and no limb symptoms warfarin 
was ceased and low dose aspirin commenced. 
 
GSV Harvest and Spiral Graft Construction 
The length of GSV required can be accurately calculated by previously described methods 
according the formula 2πr1 and is based on estimated luminal diametres on preoperative imaging. It 
has been our practice to harvest a longer section of GSV than is required and trim the conduit to the 
exact length required at laparotomy. The graft is prepared by ligating all tributaries. The harvested 
vein is incised longitudinally and all valves are excised. The rectangular patch is wrapped around a 
syringe in a spiral fashion and the cut edges are sutured together using 5.0 or 6.0 polypropylene 
suture to form a cylindrical interposition vascular conduit (fig. 2). Depending on the size of the 
vessel being reconstructed, the diameter of the conduit can be tailored by using different size 
syringes as a scaffold. For reconstruction of a CIA, a 3 or 5 ml syringe with an approximate 5 mm 
diameter is used as a scaffold while reconstruction of a CIV typically requires either a 5 ml or a 10 
ml syringe. Alternatively a chest tube can be used as the scaffold. The conduit can then be trimmed 
to form a cylindrical tube graft. Proximal and distal anastomoses are performed with 5.0 or 6.0 
polypropylene sutures. For tumours involving both iliac artery and vein, bilateral GSV harvest is 
performed and two spiral grafts are constructed using the technique described. 
 
In order to maintain patency of the venous graft, a temporary arterio-venous fistula can be 
fashioned in the groin. A tributary of the GSV and common femoral artery are anastomosed in an 
end-to-side fashion using 7-0 polypropylene suture. A 3.0 nylon suture is left lying around the 
fistula as a landmark for subsequent reversal at a later stage if required. Warfarin is used for a 
period of six months and then change to low dose aspirin if patency is maintained. 
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Ethical approval was granted by Sydney Local Health District (RPAH Zone) human research ethics 
committee and patient consent was obtained for the use of clinical imaging and photographs. 
 
Discussion 
Autologous grafts remain the preferred choice for vascular reconstruction primarily due to their low 
thrombogenicity and resistance to infection2. However, there are limitations to the use of autologous 
grafts as there are few vessels that can be readily sacrificed without significant functional sequelae. 
As far as vascular reconstruction is concerned, GSV is the workhorse of all autologous grafts and 
has been used successfully for vascular reconstruction after resection of lower limb tumours3, 
however its use for reconstruction of the pelvic vasculature is limited by major discrepancies in 
luminal calibre. Due to the lack of vessels of similar calibre that are suitable for autologous grafting 
surgeons have used biological alternatives such as bovine pericardium or even synthetic grafts for 
cancer resections involving the portal vein, aorta and inferior vena cava4,5. Autologous grafts are 
preferred, particularly in pelvic exenteration, because of the high prevalence of septic complications 
following these procedures where the operative field is typically contaminated by gastrointestinal or 
genitourinary organisms. While bovine pericardium is of low thrombogenicity, it is costly. 
Synthetic graft material is manufactured in specific sizes and custom-designed grafts are expensive. 
In addition, the use of synthetic grafts in contaminated fields increases the risk of graft infection and 
failure2. Autologous peritoneo-fascial grafts have also been used as a biological alternative for 
major venous reconstruction with low graft-related morbidity and may be a suitable option for 
reconstruction of pelvic vasculature4,6. 
 
Patients referred for consideration of pelvic exenteration are discussed at a MDT meeting 
comprising of colorectal, vascular, orthopaedic, urological surgeons as well as medical and 
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radiation oncologists and a senior radiologist. Tumour resectability is determined with pre-operative 
MRI, which also guides decision-making about the extent of pelvic sidewall resection required. 
Tumours with suspected contiguous common or external iliac artery or vein involvement are further 
assessed using CT or MR angiography or venography to confirm vessel involvement. These 
patients also routinely undergo duplex mapping of their great saphenous and femoral venous 
systems to determine suitability as an autologous vascular graft. An operative approach to tumours 
involving the lateral pelvic sidewall with en bloc iliac vessel resection has previously been 
described7 and contiguously involved common or external iliac vessels are excised en bloc with the 
tumour. The method of vessel reconstruction used is dependent on vascular surgeon preference, 
availability of lower limb vessels for grafting and the luminal diameter of the vessel requiring 
reconstruction. Where possible, the GSV is harvested and grafts constructed on a back table prior to 
delivery of the specimen, however this often proves difficult due to limited access to the limb when 
operating in the pelvis at the same time. 
 
Chiu and colleagues originally described the spiral vein graft in 1974 for the reconstruction of the 
superior vena cava8. More recently the versatility of this technique has been demonstrated in its use 
for reconstruction of the aorta1 and portal vein9. In our experience with common iliac 
reconstruction, the GSV spiral graft is useful in that it is autologous, can be tailored to suit vessels 
with different diameters by use of different size syringes as scaffolds and avoids harvest of the 
superficial femoral vein (SFV)10. A SFV autologous graft has been routinely used by our unit in the 
past, however this then relies solely on the profunda veins for deep venous drainage of the lower 
limb and carries a greater concern for leg oedema following harvest, particularly in the setting of 
previous or neoadjuvant preoperative radiotherapy as well as prior resection of primary cancers. 
Abdelsattar and colleagues5 recently reported the use of synthetic interposition grafts, femoral-
femoral bypass and primary anastomosis for reconstruction of the aortioiliac axis after resection of 
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colorectal cancer. Similar techniques have been described in case reports11,12, however these do not 
offer the advantage of an exactly matched luminal size of the graft with the vessel requiring 
reconstruction. 
 
Conclusion 
The autologous GSV spiral graft allows the surgeon to construct a conduit of specific diameter by 
use of different size syringes as scaffolds for the reconstruction of a vessel of a particular diameter. 
The use of an autologous graft may reduce the risk of graft thrombosis and infection in a 
contaminated operative field. 
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Figure 1. Magnetic resonance imaging view of a patient with a retroperitoneal leiomyosarcoma. 
 
Figure 2. Construction of the GSV spiral graft. The rectangular patch is wrapped around a syringe 
in a spiral fashion and cut edges are sutured together. 
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Figure 3. In situ GSV spiral graft (arrows) reconstruction of the right CIV. The left CIV is visible, 
as are the left CIA and left ureter (vessel loops). 
 
 
Figure 4. In situ GSV spiral graft (arrows) reconstruction of the right CIA overlying the 
reconstructed right CIV. 
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Abstract 
This article describes a novel technique for en bloc resection of locally recurrent rectal cancer that 
invades the high sacral bone (above S3). The involved segment of sacrum is mobilised with 
osteotomes during an initial posterior approach before an anterior abdominal phase where the 
segment of sacral bone is delivered with the specimen. This allows en bloc resection of the involved 
sacrum while preserving uninvolved distal and contralateral sacral bone and nerve roots. The goal is 
to obtain a clear bony margin and offer a chance of cure while improving functional outcomes by 
maintaining pelvic stability and minimising neurological deficit. 
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Introduction 
Achieving complete oncological (R0) resection is the most important predictor of long-term survival 
in patients undergoing curative surgery for recurrent rectal cancer1. The ongoing evolution of surgical 
techniques for ‘higher and wider’ multivisceral resections has been driven by surgeons seeking the 
ultimate goal of R0 resection, which is now the key consideration when deciding what constitutes 
‘resectable’ disease2,3. High sacral bone involvement remains controversial, and although en bloc 
high sacrectomy has been shown to be safe and oncologically feasible in several specialist centres, 
concerns remain about pelvic instability and the need for subsequent reconstruction, as well as 
postoperative neurological deficits associated with sacrifice of sacral nerve roots4,5. This article 
describes a novel technique for en bloc resection of the involved segment of the sacral bone and 
nerve roots only, rather than the traditional sacral amputation, with a view to preserving uninvolved 
distal and contralateral sacral bone and nerve roots.  
 
Case Presentation 
A 51-year-old man was referred to our unit with locally recurrent rectal cancer causing left sided 
intractable sciatica and weakness of ankle plantar flexion. He had previously undergone a staged 
anterior resection for rectal cancer and resection of a single liver metastasis after which he remained 
disease free for seven years. Pelvic MRI demonstrated isolated recurrence at the high rectal 
anastomosis extending posteriorly and laterally with invasion of the left sacrum from mid-S1 to S2/3 
levels (fig. 1), encasement of the left S1 and S2 nerve roots and involving the left piriformis muscle 
and internal iliac vessels. The left L5 was not involved nor were any of the right sacral nerve roots. 
The patient was reviewed at the pelvic exenteration multi-disciplinary team meeting and, given that 
high total sacrectomy was the only alternative, after neoadjuvant chemoradiotherapy he proceeded to 
surgery with a plan to resect the involved S1-S3 vertebrae of the left hemisacrum and left sided nerve 
roots en bloc with the rectum and left pelvic sidewall. The aim was to preserve the left L5, S3 and S4 
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nerves as well as all right sacral nerve roots to preserve the majority of lower limb motor as well as 
bladder function. 
 
Informed consent was obtained from all individual participants included in the study including the 
patient. 
 
Technique 
The technique includes an initial posterior prone approach followed by an abdominal approach. 
 
Posterior phase 
The patient was placed in the prone position and a dorsal longitudinal skin incision made from the 
level of L3 to S4 in the midline. Subperiosteal dissection was carried out bilaterally over L5 and 
continued on the dorsal aspect of the sacrum to S3, mobilising the gluteus maximus muscle at its 
attachment. Dissection continued further laterally on the left to expose the lateral margin of the 
sacrum. A wide laminectomy over the left hemisacrum was performed from S1 to S3. The left S1 and 
S2 nerve roots were individually ligated and divided medial to the tumour while the L5 root was able 
to be preserved.  
 
With careful reference to preoperative imaging and anatomical landmarks (i.e. sacral foramina and 
the median sacral crest) partial thickness transverse osteotomies were performed with an osteotome at 
a level just distal to the superior end plate of S1 and through the middle of the body of S3 (fig. 1). At 
this point intraoperative radiography was used to confirm the appropriate sacral levels. The 
osteotomy was extended vertically in the midline, deep to the remaining cauda equina, and a further 
longitudinal osteotomy was performed laterally through the sacrum. After again confirming 
osteotomy sites with intraoperative radiography and reference to preoperative MRI, completion of the 
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osteotomy was performed carefully, stopping when the anterior cortical bone of the sacrum was 
breeched to prevent injury to iliac vasculature and other presacral structures. This then enabled the 
involved bony segment to become mobile with only some remaining anterior sacral soft tissue. 
Hence, the involved left S1-S3 segment of sacral bone containing tumour was mobile, ready for the 
completion and delivery via the anterior approach and thus maintaining the mechanical integrity of 
the sacrum. Given the lack of proximal vascular control, this phase of the operation required 
meticulous dissection to avoid inadvertent injury to internal iliac and presacral vasculature. 
 
Abdominal phase 
The patient was turned and placed in the modified Lloyd-Davies position and a midline laparotomy 
performed. This phase of the operation has been previously described4-6. In summary, the residual left 
colon was transected proximal to the neorectum and bilateral ureterolysis performed. The left pelvic 
sidewall was dissected6, with ligation and division of the anterior division of the left internal iliac 
artery (preserving the superior gluteal artery) and internal iliac vein and its tributaries. L5 was 
identified, dissected free and protected and the S1 nerve root was transected to free the L5 nerve root 
throughout its course. The presacral fascia was incised and the posterior osteotomies identified and 
joined circumferentially (fig. 2). A redo ultra-low anterior resection was performed and the specimen 
(fig. 3) was delivered through the abdominal wound. 
 
Postoperatively the patient had a complete left S1-2 nerve root palsy and normal motor function in 
the right lower limb. He was able to mobilise independently at the time of discharge on day 23 after 
surgery. Pathological examination of the specimen demonstrated complete oncological resection. 
 
Discussion 
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More recent experiences with high sacrectomy at specialised centres have produced encouraging 
oncological and survival outcomes in patients with locally advanced or recurrent rectal cancer4,5, who 
were traditionally excluded from curative surgery2,7. High sacral bone involvement should not 
represent an absolute contraindication to surgery, however the procedure may carry significant 
morbidity, particularly when S1 and S2 nerve roots are sacrificed4,8. 
 
Modified approaches to traditional sacral amputation have been developed with a view to reducing 
morbidity and improving function while still achieving a safe resection margin. These include 
sacrectomy via the abdominal approach to avoid a prone phase in selected patients, hemisacrectomy 
with preservation of contralateral sacral nerves, and resection of the anterior cortical plate only of the 
sacrum to preserve the nerve roots and posterior bone9-12. The technique described in this report may 
be useful as a less morbid alternative to high sacral amputation in selected patients with focal 
involvement of the high sacrum. Resecting only the involved segment allows preservation of distal 
and contralateral sacral nerve roots and also maintains sacropelvic stability. By doing the prone phase 
first followed by the abdominal phase (with specimen delivery from the front) a smaller ‘segmental 
sacrectomy’ is possible without complete amputation, where the size of the specimen would prevent 
removal through the smaller sacrectomy.  
 
The main limitation of this technique is that the posterior approach must be done first, with limited 
vascular control, to allow delivery of the specimen. Furthermore, determination of the osteotomy 
sites to achieve complete oncological resection is based on preoperative MRI and requires specialised 
multi-disciplinary team input. This approach should therefore be considered only in highly selected 
patients at specialised centres with expertise in reoperative pelvic surgery and composite sacral 
resection. 
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Figure 1. Axial (A) and sagittal (B) magnetic resonance imaging views of a patient with recurrent 
rectal cancer involving the left sacrum at S1 and S2 levels. Osteotomy sites are shown (white lines). 
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Figure 2. Anterior view of the bony sacral defect after delivery of the specimen during the 
abdominal phase. Left common and external iliac veins are seen with blue vessel loops. Divided 
ends of the left internal iliac vein and artery are seen. 
 
Figure 3. Tumour involving sacral bone (horizontal arrow), nerve roots and neorectum. The left 
internal iliac artery is also visualised (vertical arrow) 
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THESIS DISCUSSION 
Pelvic exenteration involves en bloc resection of multiple pelvic organs, often with excision of 
neurovascular and bony tissues at the periphery of the pelvis with complex reconstruction, and may 
be associated with significant postoperative morbidity. While patients who underwent pelvic 
exenteration under pioneering surgeons in the 1950s and 1960s experienced remarkably high rates 
of morbidity and mortality (chapter 1), contemporary literature suggests that pelvic exenteration 
offers a chance of cure to patients who would otherwise be palliated, and can be performed with 
acceptable morbidity and quality of life1,2. This thesis aimed to investigate rates of postoperative 
complications in patients who underwent radical pelvic surgery at the pelvic exenteration unit at 
Royal Prince Alfred Hospital, Sydney, since the unit was established in 1994. The major findings 
presented in chapter 2 are that the rate of urinary conduit-associated complications, especially 
urinary leaks and sepsis, are higher after pelvic exenteration than after cystectomy alone for primary 
bladder malignancy. Several factors may contribute to the higher rate of urological morbidity, 
including a history of pelvic irradiation, major intraoperative blood loss, cardiac disease, diabetes 
mellitus, as well as the type of urinary reconstruction. Chapter 3 found that en bloc lateral pelvic 
compartment excision allows complete oncological resection in 69% of patients undergoing 
planned curative surgery with acceptable postoperative morbidity (major and minor complication 
rates were 28% and 79%, respectively) and demonstrated that en bloc excision and reconstruction 
of the common or external iliac vessels is feasible, with no intraoperative or 30-day mortality, 96% 
overall graft patency at 1 year and 0% limb loss in a group of 21 patients. Chapter 4 described two 
novel techniques developed at the RPA exenteration unit (spiral saphenous vein graft for 
reconstruction of major pelvic vessels and segmental sacrectomy for tumours with high sacral 
involvement) in an attempt to reduce postoperative morbidity. 
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In contemporary literature, en bloc cystectomy is required in 20-53% of patients undergoing pelvic 
exenteration3-5. Russo and colleagues reported a urological morbidity rate of 17% in a cohort of 47 
patients who underwent urinary diversion in the context of pelvic exenteration6, which included two 
patients with urine leakage from the uretero-ileal anastomosis. Similar experiences have been 
reported by other centres with urological morbidity rates between 9 and 24% for ileal or colonic 
conduit reconstruction, and urinary leak rates between 7 and 16% (chapter 1, table 1)4,7-9. The study 
presented in chapter 2 reported an overall conduit-related complication rate of 59% after 
exenteration (48% for patients with primary malignancies and 67% for patients with recurrent 
tumours, P=0.035). This rate would appear higher than those published by other exenteration units, 
however most studies have not included rates of urinary tract infection or urosepsis which occurred 
in 21 and 50% of patients who had pelvic exenteration for primary and recurrent tumours, 
respectively, in this thesis. Khan and colleagues recently presented a series of 60 patients 
undergoing urinary reconstruction in the context of pelvic exenteration for rectal cancer, reporting a 
postoperative urological morbidity of 55% and a urinary tract infection rate 37%, figures which are 
more consistent with the results of our study10. Other recent series by Goldberg and Tan have 
documented rates of urinary tract infections of 25 and 36%, respectively8,11. 
 
It remains unclear which patient or operative factors may predict urological morbidity. Preoperative 
pelvic radiation therapy has been associated with higher rates of urological morbidity following 
exenteration in gynaecological literature12, however in a series of 126 patients with en bloc 
resection of urological organs (including 80% with a urinary conduit), Stotland and colleagues 
found no association between radiotherapy and urological morbidity (P = 0.61)13. In this thesis 
major blood loss and prior pelvic radiotherapy independently predicted conduit-associated 
complications after pelvic exenteration (P= 0.002 and 0.035), and cardiac disease, diabetes, as well 
as type of urinary reconstruction have been implicated. 
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Urinary leaks remain a major challenge in pelvic exenteration patients, with implications for length 
of stay and possibly long term patient survival4. In this thesis the rate of postoperative urinary leak 
was 3% in cystectomy patients and 11% in pelvic exenteration patients (6% for primary tumours, 
14% for recurrent tumours). A higher incidence of urinary leaks after pelvic exenteration surgery is 
in keeping with recent literature, with rates up to 20% documented by other authors11 (chapter 1, 
table 1). Interestingly, there was no difference in the rate of urine leaks between the PE for primary 
malignancy and cystectomy alone group (P = 0.395) in this thesis. It is likely that the higher 
morbidity after exenteration carried out for recurrent cancer reflects the more advanced disease and 
the more complex nature of treatment (radiotherapy and major re-operative surgery), rather than the 
extent of the resection alone. Small numbers of patients with urinary leaks prevented identification 
of any significant predictors of urinary leaks. 
 
In the ongoing pursuit of clear margins, some specialised units have developed experience with 
even ‘higher and wider’ lateral resections for tumour involvement of the common and external iliac 
vessel, and extending to the sciatic nerve and ischial bone (chapter 3). Abdelsattar and colleagues at 
the Mayo clinic reported R0 resection in 7 of 12 patients undergoing en bloc resection and 
reconstruction of the aorta or iliac vessels with no 30-day mortality, 75% morbidity and 100% graft 
patency at 4 years13. Chapter 3.2 presented a series of 21 patients requiring common or external 
iliac vessel resection and reconstruction which produced an R0 resection rate of 38% and a median 
overall survival of 34 months. Postoperative complications related to the vascular reconstruction 
were significant, occurring in 52% of patients with 24% of patients returning to theatre. However, 
importantly the overall graft patency at 1 year was 96%, limb loss was 0% and there was no 
intraoperative or 30-day mortality. These series represent selected subgroups of patients at 
specialized units and suggest that radical vascular excision and reconstruction may be performed 
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safely in this setting. Improved surgical techniques and patient selection are critical if such radical 
resections are to adopted routinely. Investigation of vascular reconstruction techniques after iliac 
vessel excision is ongoing and includes the novel use of saphenous vein spiral grafts (chapter 4.1) 
and bovine pericardium. 
 
Recently several specialised exenteration units have demonstrated the feasibility of high sacrectomy 
(above the S3 vertebrae)14,15. If the level of sacral transection is below the level of the sacroiliac 
joint (below S3), the sacrectomy is performed trans-abdominally using osteotomes16, giving better 
access to the pelvic sidewall and control of the iliac vasculature, and permits a more lateral 
dissection of the sciatic nerve as it traverses lateral to the greater sciatic foramen. For more 
proximal sacral bone involvement the patient is turned prone after the abdominoperineal phase for 
traditional prone sacrectomy. In contemporary literature high sacrectomy, although still 
controversial, has been shown to produce 5-year survival rates between 38 and 43% (chapter 1, 
table 2).  
 
In an attempt to reduce the morbidity associated with nerve sacrifice and pelvic instability after 
traditional sacrectomy, several new techniques have been developed including abdominal 
sacrectomy16, hemisacrectomy17, and resection of the anterior cortical plate only of the sacrum18. A 
novel technique for tumours invading high sacral bone described in chapter 4.2 involves posterior 
mobilisation of the involved sacral segment with osteotomes followed by a completion abdominal 
approach where the segment of sacral bone is excised en bloc with the pelvic mass. This minimises 
nerve root sacrifice and preserves mechanical integrity of the pelvis.
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The majority of pelvic exenteration patients will require both a permanent colostomy and urostomy 
and experience loss of sexual function, with many undergoing prolonged periods of rehabilitation. 
Furthermore, major bony or neurovascular resections may impair lower limb function and therefore 
limit mobilisation. The potential morbidity associated with this radical surgery which has been 
investigated in this thesis has obvious implications for postoperative QoL which, in addition to any 
anticipated survival benefit, must be weighed against the QoL and survival that can be expected 
when a palliative approach is adopted. As increasingly radical resections are performed, including 
high sacrectomy, lateral neurovascular excision and hemipelvectomy, it becomes increasingly 
important to establish what constitutes an ‘acceptable’ postoperative QoL from an individual 
patient’s perspective. While survival advantages of pelvic exenteration have been confirmed, 
contemporary literature reporting QoL after pelvic exenteration is limited19. This represents a gap in 
the literature and requires further investigation to improve patient selection and surgical decision 
making.  
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Abstract 
Background: Urine leak following pelvic exenteration for locally advanced pelvic malignancy is a 
major complication leading to increased mortality, morbidity and length of stay. We reviewed our 
experience and developed a diagnostic and management algorithm for urine leaks in this patient 
population. 
Methods: Consecutive patients who underwent en bloc cystectomy and conduit formation as part of 
pelvic exenteration at a single quaternary referral centre from 1995 to 2012 were reviewed. Patients 
with urine leak were identified. Medical records were reviewed to extract data on diagnosis and 
management and a suggested clinical algorithm was developed. 
Results: Of 325 exenterations, there were 102 conduits, of which 15 patients (15%) developed a 
conduit related urine leak. Most (14/15) patients were symptomatic. Diagnosis was made by drain 
creatinine studies (12/15) and/or imaging (15/15). Management comprised of conservative 
management, radiologic urinary diversion, early surgical revision and late surgical revision in 3, 11, 
2 and 1 patients respectively. Important lessons from our 17 year experience include a high index of 
suspicion in a patient who is persistently septic despite appropriate treatment, the importance of 
regular drain creatinine studies, CT (computer tomography) with delayed images (CT intravenous 
pyelogram) when performing a CT for investigation of sepsis and early aggressive management 
with radiologic urinary diversion to facilitate early healing. 
Conclusion: Urine leak after pelvic exenteration is a complex problem. Conservative management 
usually fails and early diagnosis and intervention is the key. It is hoped that our algorithms will 
facilitate diagnosis and subsequent management of this group of patients. 
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Introduction 
The management of locally advanced and recurrent pelvic malignancy is challenging1-3. Extensive 
multi-visceral resection is often required in order to achieve clear resection margins (R0 resection), 
which is now well established as the single most important predictor of long-term survival4. In 
patients where there is involvement of the trigone of the bladder or where the anticipated urinary 
function is likely to be poor, en bloc cystectomy is indicated with urinary diversion in the form of 
ileal or colonic conduit5. Recent large exenterative series suggest that this may be necessary in 30-
50% of all patients undergoing curative resection for locally advanced or recurrent pelvic cancer6,7. 
Leakage of urine from a newly formed conduit is a major postoperative complication. In an earlier 
study from our institution, a conduit related urine leak rate of 16% was reported6, which is a 
disparately different result from that within contemporary urological literature, where rates of 2-6% 
are reported8,9. This is likely to be attributable to our cohort of patients having re-operative pelvic 
surgery with multi-visceral resection in an extensively irradiated field. However, this experience is 
not unique to our institution as high leak rates have also been reported following pelvic exenteration 
for urological and gynaecological cancer10-12. Urological leaks are a considerable source of 
morbidity following pelvic exenteration, leading to increased resource consumption as necessitated 
by prolonged in and outpatient management, as well as a shorter median survival6. In view of our 
experience with the management of urine leaks, the lack of consensus in appropriate management 
and an increasing interest in exenterative radical resection13, it was felt that a suggested diagnostic 
and management algorithm may facilitate the management of this complex problem. With this in 
mind we reviewed our experience with a view to develop a suggested clinical algorithm for the 
diagnosis and management of urine leaks after pelvic exenteration surgery. 
 
Patients and Methods 
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Patients who underwent pelvic exenteration surgery for locally advanced or recurrent pelvic 
malignancies (including rectal cancer, SCC and sarcoma) at Royal Prince Alfred Hospital, between 
December 1995 and September 2012 were identified. Operations were considered exenterative 
when there was en bloc resection of at least one adjacent organ, as defined by Heriot and 
coworkers14. Those who had an ileal or colonic conduit and subsequently developed a postoperative 
urine leak formed the study cohort. A urine leak was defined as the presence of creatinine rich 
effluent from abdominal drains or wound sites, and/or evidence of contrast extravasation from the 
conduit or ureteric anastomosis identifiable on imaging. Urine leaks with contrast extravasation 
arising from the ureteroenteric anastomosis were considered ‘anastomotic leaks’, whereas contrast 
extravasation from anywhere else on the conduit (eg the distal conduit staple line) were considered 
‘conduit leaks’. 
 
Patient medical records were reviewed for preoperative urological history, type of conduit, cause of 
leak, diagnosis, and subsequent investigations and management. Urine leaks were identified as early 
or late according to time to diagnosis and categorised as controlled or uncontrolled based on the 
patient’s drain and urine output volumes. The choice of day 6 as the cut off point for early versus 
late leak diagnosis was based on a study by Hensle et al15 and because it would fit in with our 
general approach to management in that leaks within a week of surgery will be considered for early 
surgical revision. The first suspicion of a urine leak was noted, and from this the delay to diagnosis 
was estimated; defined as the period of time between initial suspicion and diagnosis. Complications 
following image-guided investigations or interventions such as sepsis were recorded. Sepsis was 
defined as proof of bacteraemia or clinical suspicion of sepsis, as well as the signs and symptoms of 
the systemic inflammatory response syndrome16. Persistent urosepsis is defined as sepsis of the 
urinary tract that does not resolve despite an appropriate course and duration of treatment including 
antibiotics and general supportive measures. For the purposes of this study, conservative 
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management refers to any supportive management that did not require any radiologic or surgical 
intervention. Radiologic urinary diversion refers to any radiological interventions including the 
insertion of percutaneous nephrostomies for urinary diversion or percutaneous drain insertion 
whereas surgical intervention (early or late) refers to patients who required operative interventions 
such as conduit revision. 
 
Ethics approval for this study was granted by the Sydney Local Health District (RPAH Zone) 
human research ethics committee. 
 
Surgery 
The decision to perform en bloc cystectomy and form a urinary conduit was based on preoperative 
discussions at a multidisciplinary exenteration meeting. The choice of reconstruction was at the 
discretion of the operating surgeon at the time of surgery, depending on evidence of radiation injury 
to small bowel and whether or not there was an established colostomy. Conduits were constructed 
according to standard technique. In summary, the isolated ileal or colonic segment was stapled 
closed at the blind abdominal end, the ureteroenteric anastomoses were constructed using the 
Bricker technique over ureteric catheters17 and a Brooke (end) or Turnbull (loop) stoma created. 
Depending on the surgeon, ureteric catheters were sutured in place to the stoma or within the 
conduit to prevent migration. At least one intra-abdominal drain was placed in each patient, and 
antibiotics were administered routinely for 5 days. Drain fluid creatinine analyses were routinely 
performed on day 2 and repeated regularly between every 5 to 7 days and as clinically indicated. 
Contrast radiology of the urinary tract was performed largely to confirm urinary leaks in the 
presence of clinical suspicion, although routine imaging was also performed in selected patients 
depending on surgeon preference. Imaging modalities included computer tomography intravenous 
pyelogram (CT IVP), CT conduitogram,  “stentogram” and nephrostogram. A CT conduitogram is a 
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contrast study of the conduit where the contrast is directly administered into the conduit via a Foley 
catheter whereas a “stentogram” is a fluoroscopic examination of the urinary tract that involves 
administration of contrast via the externally draining surgically placed ureteric catheters.  
 
Fluoroscopic screening is carried out as the contrast is being excreted naturally from the renal pelvis 
into the conduit. A nephrostogram (CT or fluoroscopic) is a contrast study whereby the renal pelvis 
is directly cannulated for contrast examination. This is usually performed at the time of insertion of 
percutaneous nephrostomy. 
 
Statistical analysis on this cohort of patients was not done because of the descriptive nature of this 
study and the small number of patients within the cohort.  
 
Results 
There were 325 patients who underwent a pelvic exenteration during the study period, 102 (31%) of 
who had an ileal or colonic conduit formed for urinary diversion. Of these, 18 developed a urine 
leak, however, three patients were excluded for non-conduit related leaks. One had a contained 
bladder leak (after partial cystectomy) and two had ureteric leaks from inadvertent ureteric injury. 
Of the 15 included cases (15% of all conduits), 12 were male with a median age of 62 (IQR = 56-66 
years). 11 urine leaks were from ileal conduits (14% of all ileal conduits) and 4 were colonic (17% 
of colonic conduits). 7 patients (8% of conduits) had a urine leak from the ureteroenteric 
anastomosis, while 8 (9%) leaked from the conduit itself. In five cases there was an identifiable 
cause for the urine leak: due to an ischaemic conduit in one case, stomal stenosis of an existing 
ileostomy in another, two were iatrogenic from inadvertent perforation from a conduit catheter and 
one early leak was thought to be related to the technical construction of the ureteroenteric 
anastomosis. Table 1 summarises patient demographics. 
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Diagnosis 
The most common clinical manifestations of urine leak were sepsis (8 patients), increased drain 
output (6), leakage from the sacral wound (5) and decreased urine output (4). Of the four patients 
who had decreased urine output, three also had an increase in drain output or significant wound 
discharge. One patient had an asymptomatic urine leak, detected on routine stentogram on day 11 
postop to check anastomotic integrity. The median time from operation to diagnosis of urine leak 
was 12 days (IQR = 9-37 days), and using our definition of 6 days as a cut off, two patients were 
considered to have an early leak, while 13 patients had late leaks.  
 
The initial diagnosis of a urine leak was made on the basis of abdominal drain creatinine in 11 
patients, and 10 of these were confirmed by imaging within 3 days. In the remaining 4 patients, two 
had their abdominal drains removed prior to leak diagnosis, one did not have drain creatinine 
studies ordered and another was diagnosed by routine stentogram. 
 
In total, the site of leak was confirmed in 13 patients, 3 by CT IVP and 10 by CT conduitogram. In 
the remaining two cases the site of leak was not confirmed until a nephrostogram was performed at 
the time of percutaneous nephrostomy tube insertion. Imaging or radiological intervention related 
complications occurred in seven patients and were all sepsis related requiring intravenous 
antibiotics. Delay in diagnosis occurred in only one patient who did not undergo drain fluid 
creatinine analysis despite the suggestive nature of the percutaneously inserted drain fluid effluent. 
The delay in diagnosis was 10 days in this patient. 
 
Management 
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Of 15 patients diagnosed with a urine leak, three were managed conservatively. Two had small, 
contained urine leaks where management involved prolonged drainage by the conduit catheter and 
the ureteric stents inserted at the time of exenteration. One of these patients had an asymptomatic 
leak detected on routine screening stentogram, which resolved spontaneously a week later on repeat 
stentogram. A third patient was non-compliant with treatment and medical recommendations, and 
was therefore also treated conservatively despite initial plans for surgical conduit revision.  
 
Two patients with early urine leaks underwent early surgical revision. In one patient, the leak 
resolved following repair of the conduit at the site of leak. The second patient had an iatrogenic 
conduit leak as a result of a Foley conduit catheter perforating the staple line at the blind end of the 
conduit. The catheter was inserted by the bedside to facilitate urinary drainage from an oedematous 
conduit. The site of perforation by conduit catheter was repaired and both ureteroenteric 
anastomoses were also reinforced but this patient went on to develop urine leak from a second site 
at the right ureteroenteric anastomosis 24 hours later, which required ongoing urinary diversion in 
the form of percutaneous nephrostomy.  
 
Eleven patients were managed radiologically which involved a combination of percutaneous 
nephrostomy for urinary diversion, percutaneous drainage or trans-conduit drainage for conduit 
leaks if needed. This included the patient who developed a leak from a second site following early 
surgical revision. The leak resolved in seven of these patients who had nephrostomy tubes inserted 
for a median duration of 40 days (IQR = 21-57 days). One patient’s leak did not settle with drainage 
and underwent a late operative revision where the conduit was excised and refashioned. Three 
failed to heal despite prolonged drainage and developed progressive disease whilst they were in 
hospital. All were palliated with long term drainage. In one patient, palliative management involved 
ongoing drainage of the collection system by ureteric stents and percutaneous drainage with a drain, 
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while the other two patients had permanent percutaneous nephrostomy tubes placed following 
ureteric lumen occlusion with a combination of sclerosis and coil embolisation.  
 
Discussion 
The purpose of this study was to review our experience with urine leaks after pelvic exenteration so 
as to develop a possible clinical algorithm for the diagnosis and management of this challenging 
problem (Figures 1 & 2). While we report relatively small numbers of postoperative urine leaks, 
this represents one of the largest series in the literature. Surprisingly, the urological literature in this 
area is limited,18-21 and lacks comprehensive guidelines for the management of this problem, 
particularly in our subset of patients where extensive multi-visceral resection has been performed in 
multiple compartments of the pelvis in the setting of high doses of prior radiation therapy. Within 
the literature, urine leaks after urological surgery often spontaneously resolve with external 
drainage. However we have not found this to be the case in pelvic exenteration patients. This may 
be related in part to the extensive surgery and a history of prior radiotherapy, although small 
numbers would limit our ability to draw this conclusion. 
 
Factors that contributed to or caused a urine leak were identified in five patients, including an 
ischaemic conduit, unrecognised stomal stenosis of a prior ileostomy used for an ileal conduit, 
technical error and two cases of conduit perforation related to the use of conduit catheters. 
Awareness of these factors should prompt early suspicion and be points of caution in all patients 
with urinary diversions. Conduit drainage using conduit catheters should be performed using a 
multiply fenestrated catheter that has been secured in place to avoid inward migration of the 
catheter and prevent catheter-related erosion or damage to the conduit as the conduit decompresses. 
Where there is a delay in diagnosis, urine leaks tend to be less likely to heal spontaneously and have 
historically been associated with high morbidity15. Routine drain fluid creatinine studies should be 
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performed on day 2 after surgery to ensure early detection of urine leaks and it is recommended that 
this be repeated regularly and in the presence of signs such as high drain output, persistent urinary 
sepsis, low urine output or wound discharge. Many exenteration patients drain large amounts of 
fluid via abdominal drains due to extensive lymphadenectomy and disrupted lymphatic drainage. 
This may mask an underlying leak unless a high index of suspicion is maintained. In one case, a 
delay to diagnosis occurred because of high drain output attributed to a lymphocele. Thus, drain 
fluid creatinine analysis should be performed routinely and repeated regularly in this population and 
a high index of suspicion should be maintained. Sepsis was another common presentation in our 
series, and in several of these cases, an original diagnosis of urinary tract infection was made. 
Although it is common following the formation of a conduit, persistent urinary sepsis is suspicious 
and patients should be further investigated. In this setting, drainage effluent should be cultured to 
identify bacterial infection and guide choice of antibiotic therapy. 
 
The use of routine imaging in postoperative assessment of patients with urinary diversions is 
debatable22-25. The decision to perform imaging will be an individual surgeons preference, and 
although contemporary urological literature does not support the use of routine imaging of the 
urinary tract, the utility of this in an exenteration population is unclear. For the investigation of 
persistent urinary sepsis or a positive drain creatinine study, the use of CT IVP visualising the renal 
collecting system is preferred. This not only demonstrates pelvic collections, but also confirms the 
diagnosis of a leak, the site of a leak as well as demonstrating the relational anatomy. Should a CT 
IVP fail to confirm or diagnose a leak despite clinical suspicion, a CT conduitogram or a 
stentogram are useful second and third line investigations. Following nephrostomy tube insertion, a 
nephrostogram can be performed to diagnose the site of a leak, and in some cases a conduitoscopy 
may be necessary to confirm this as seen with the current study. However, conduitoscopy should be 
performed judiciously as the irrigating fluid during conduitoscopy can disperse at the time of the 
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procedure. In our experience, this has not been a concern as this investigation is typically reserved 
for when the site of leak remains unclear despite aforementioned investigations or when the leak 
remains uncontrolled and is therefore performed late.     
 
There are several management options in the approach to postoperative urine leaks18. Early in our 
exenterative practice the management of urine leaks was more conservative with prolonged 
drainage and an observation-based approached. However, it became apparent that this patient 
population is different and that a more aggressive, interventional approach is needed. There is no 
consensus within the urological literature about the classification of urine leaks: Schmidt et al 
defined early urine leaks as those occurring within 10 days following surgery19, while Hensle et al 
defined an early leak as within 6 days postoperation15. We have chosen to classify urine leaks based 
on a cutoff of 6 days as this fits in with our surgical approach whereby a leak within a week of 
surgery is generally considered a technical error and patients are likely to benefit from early 
revision. Of note, most patients were diagnosed late, where the surgical window of opportunity is 
frequently lost and in this case maximal urinary diversion of urine should be achieved by insertion 
of bilateral percutaneous nephrostomy tubes26-28. A driving force behind the evolution in leak 
management in our institution relates to the observation that drainage with percutaneous 
nephrostomy often results in a very prolonged inpatient admission (median of 40 days, IQR = 21-57 
days). Thus, surgical revision should be considered where possible, although the number of patients 
who required surgical revision was small and would limit our ability to draw this conclusion.  
In our opinion ongoing sepsis from a urine leak, albeit controlled, is an adverse prognostic indicator 
akin to anastomotic bowel leaks. The increased risk of local recurrence after bowel anastomotic 
leaks is well described29. Although small numbers within this study precludes statistical analysis, 
the rapid disease progression in three patients with urine leaks in this series is alarming despite only 
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having microscopically involved margins. It may be that ongoing pelvic sepsis and pro-
inflammatory cytokines play a role in accelerated tumour cell growth and proliferation30,31. 
 
For interventions involving the urinary tract, particularly during the insertion of percutaneous 
nephrostomy tubes, there is known risk of sepsis and thus antibiotic cover is recommended. At the 
Memorial Sloan-Kettering Cancer Center, Russo and colleagues recommend single dose IV 
gentamicin during ureteric stent removal in exenteration patients21. In our series 7 (47%) patients 
developed sepsis following image-guided investigation or intervention, of which three occurred 
following an investigation alone (for example conduitogram). We would therefore extend Russo 
and colleagues’ recommendation to include all radiologic examinations of the urinary tract. 
 
Based on our experience, the suggested diagnostic (figure 1) and management (figure 2) algorithms 
were developed with the aim of providing some recommendations for the management of this 
complex problem. This is a heterogeneous group of patients and the approach to a postoperative 
urine leak will vary widely following considerations of various other clinical and patient factors. 
 
Clinical algorithms for the diagnosis and management of urine leaks following pelvic exenteration 
surgery were developed in view of the considerable experience that our institution has developed in 
managing this complex problem. Central to the management of these patients is the maintenance of 
a high index of suspicion and to further investigate patients with persistent urinary sepsis, increased 
drain outputs or wound discharge especially in the setting of decreased urine output. An early 
aggressive approach to management with consideration for early surgical revision or radiologic 
urinary diversion will expedite resolution of urine leakage thereby reducing morbidity 
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Figure 1. Clinical algorithm for the diagnosis of urine leaks 
 
 
Figure 2. Clinical algorithm for the management of urine leaks 
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Table 1. Summary characteristics of patients with urinary leaks following surgery 
 
Characteristic n (%) patients with leak 
Age  
<70 12 (80) 
>70 3 (20) 
Gender  
Male 12 (80) 
Female 3 (20) 
Conduit  
Ileal 11 (73) 
     Anastomotic leak 5 
     Conduit leak 6 
Colonic 4 (27) 
     Anastomotic leak 2 
     Conduit leak 2 
Timing  
Early leak (≤ 6 days) 2 (13) 
Late leak (> 6 days) 13 (87) 
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Table 2. Case details of patients with urinary leaks after surgery  
F female, M male, APR abdominoperineal resection, AR anterior resection, LAR low anterior resection, ULAR ultra low anterior resection,          
A anterior, P posterior, C central, LL left lateral, RL right lateral, AC adenocarcinoma
Patient Prior Surgery Radiotherapy Exenteration Final Histology Leak Diagnosis 
(Day) 
 Prior Neoadj.    
1 APR + - Total AC 37 
2 LAR, APR - + A,C,LL,P AC 34 
3 Hartmann’s + - A,C,P AC 9 
4 Primary pelvic exenteration - + A,C,LL AC 7 
5 Primary pelvic exenteration + - A,C AC 12 
6 AR + - A,C AC 5 
7 APR + - A,C,P AC 52 
8 Primary pelvic exenteration + - Total AC 50 
9 ULAR + - A,C,LL,P AC 63 
10 ULAR + - Total AC 6 
11 Primary pelvic exenteration + - A,C,LL,P Anal SCC 14 
12 Hartmann’s + + A,C,P AC 34 
13 Radical hysterosalpingo-
oophorectomy 
+ - A,C Cervical SCC 11 
14 Partial exenteration + - A,C,RL,P Embryonal 
rhabdomyosarcoma 
10 
15 APR + - Total AC 9 
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